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Background 
 
“Early detection (of cancer) is and will continue to be the single best way to significantly 
improve therapeutic outcomes” (1). This, however, is a major challenge. Many cancerous 
tissues and especially their early stages can be difficult to visualize for a physician because 
their appearance under white light illumination can be similar to that of normal tissues. 
Conversely, advanced cancers which are visible under white light illumination can have 
margins that are invisible due to tumor cells that invade into the surrounding normal tissues. 
This can hamper detection and complete surgical resection, both affecting therapeutic 
outcomes. Hence, there is a need to better visualize cancers and their extent. 
 
In vivo optical imaging of fluorescence 
 
One approach that can enhance the capability of the physician to visualize early cancers 
is the administration of a tumor-selective fluorescent marker. The tissue can then be 
illuminated with light of an appropriate wavelength to excite the marker and the resulting 
fluorescence can be detected using a sensitive camera.  
 
Fluororescent markers, on a molecular level (as shown in the energy level diagram in 
Fig. 1), can absorb certain wavelengths of light and thereby excite one of two electrons that 
are ‘paired’ (i.e. electrons with opposite spin orientation) from the ground singlet electronic 
state (S0) to the first or second singlet electronic state (S1, S2) (2). Generally, following 
excitation the electron non-radiatively decays to the lowest vibrational energy level (v = 0, 1, 
2, etc.) of the first singlet electronic state, a process that is called internal conversion.  In 
tissues, most commonly, fluorescence is the emission of light when the excited electron in 
the first singlet state, returns to the ground singlet state.  
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Fig. 1  Energy level diagram  
 Absorption takes place in the order of 10
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-15 s, internal conversion takes in the order of 
10-12 s and the average period of time an electron remains in the excited state before it decays 
and emits fluorescence, i.e. the fluorescence lifetime, is around 10-8 s. As a result of these 
time scales absorption takes place from a single equilibrated ground electronic and 
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vibrational state to various excited electronic and vibrational states. On the other hand 
fluorescence takes place from a single equilibrated excited electronic and vibrational state to 
the various vibrational states of the ground singlet electronic state. Hence, the absorption 
spectra is indicative of the vibrational levels of the excited electronic state and the 
fluorescence emission is indicative of the vibrational levels in the ground electronic singlet 
state, as illustrated in Fig. 2 that shows both absorption and emission spectra for the 
fluororescent marker Protoporhyrin IX.  
Fluorescence is not the only de-excitation mechanism for a molecule in the excited 
singlet state. Instead, it may decay non-radiatively, or may undergo intersystem crossing. In 
the latter case, the spin orientation of the excited electron in the first singlet state flips to the 
same orientation as the paired electron in the ground state so that the molecule undergoes 
conversion to the first triplet electronic state, T1. Emission of light due to transition from T1 
to the ground singlet state S0 is called phosphorescence. This has a longer wavelength 
compared to fluorescence due to a loss of energy associated with intersystem crossing. 
Because transition from T1 to the ground singlet state S0 is quantum-mechanically forbidden, 
the decay rate of this state is orders of magnitude smaller than fluorescence. Thus, the 
phosphorescence signal is small compared to fluorescence and hence detection of 
fluorescence is often preferred.   
Alternatively, the electron in the first triplet state may interchange energy through 
collisions with ground state oxygen that has two ‘unpaired’ electrons with the same spin 
orientation and thus a triplet ground state (3O2). Here, the electron of the fluorescent marker 
returns to the ground state and transfers energy with oxygen that causes a spin flip and 
hence intersystem crossing to singlet state oxygen or (1O2). This molecule is cytotoxic and in 
an aqueous environment very short lived (<<1μs). Singlet state oxygen is believed to be the 
main cytotoxic agent responsible for cell death in Photodynamic therapy (PDT), which is an 
experimental therapy for malignancies and other indications (3). If fluorescent markers are 
used in PDT they are generally called photosensitizers, although not all fluorescent markers 
are photosensitizers and vice versa. 
Due to these photophysical and photochemical properties some fluorescent markers 
can thus be used for fluorescence diagnostics of malignancies, which is the primary focus of 
this thesis.  However, they can also be used for the treatment of malignancies, which is only 
briefly touched upon within the here presented work.  
 
Optical imaging of fluorescence has been under investigation for the detection of 
various malignancies using either exogenous fluorescent markers or endogenous 
autofluorescence, for over 2 decades (4-6). In most applications the diagnostic accuracy 
obtained has been quite variable. This was mainly due to low fluorescence contrast between 
normal and tumor tissue, caused by non-specific uptake of more traditional fluorescent 
markers as fluorescein (7) and Photofrin™ (8). These relied on rather passive targeting 
strategies and generally depended on differences in the vasculature or pharmacokinetics of 
tumor vs. normal tissues. 
 
Currently, there are several efforts underway to develop fluorescent markers with 
improved properties.  An ‘ideal’ fluorescent marker for in vivo diagnositics should have a 
tumor selective uptake with a high tumor-to-normal ratio. It should retain in tumor tissues 
long enough so that imaging is possible over a relatively flat portion of the pharmacokinetic 
window. However, it should be cleared from the vasculature fast enough to avoid unspecific 
leakage during surgical resection. The marker should be biocompatible and non-toxic so that 
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it can be administered systemically without side effects.  To induce a strong fluorescence 
signal a high probability to absorb excitation photons (i.e. molar absorption coefficient), a 
high fluorescence quantum yield and a low triplet state yield are preferred. To be able to 
image multiple fluorescent markers simultaneously one should be able to tune the excitation-
emission wavelength, and emission should take place with a high spectral intensity.  
 
A fluorescent marker that has several, but not all, of the above properties is 5-
aminolevulinic acid (ALA) induced protoporphyrin IX (PpIX). For this reason it has been 
investigated extensively in the literature as well as in this thesis.  PpIX is produced inside 
cells that are involved in the heam biosythesis. ALA is naturally present in all mammalian 
cells and through various intermediate steps induces mitochondrial production of PpIX. 
Subsequently, an iron atom is inserted into the PpIX molecule under control of the enzyme 
ferrochelatase to produce heam. When ALA is exogenously administered selective PpIX 
accumulation has been observed in various cancers and its earlier stages. Theories have tried 
to explain this tumor selectivity, contributing factors may be; an increased ALA uptake, a 
reduction of ferrochelatase, and reduction of iron in cancerous vs. normal tissues. But it has 
been suggested that these theories could be oversimplified and that that the reasons for 
selective PpIX uptake may be more complex (9). The excitation and emission spectra of 
PpIX are shown in Fig. 2. ALA-PpIX fluorescence imaging has had various degrees of 
success experimentally and clinically. It has been used for detection of basal cell carcinomas, 
bladder cancer and cervical intraepithelial neoplasia. Currently, the most promising 
oncological application of ALA-PpIX, is fluorescence image-guided resection of malignant 
gliomas.  Recent  results of a multi-centre Phase III clinical trial in 270 patients demonstrated 
that patients allocated to fluorescence guidance had double the 6-month progression free 
survival rates as compared to those allocated to white light (41.0% [32.8-49.2] vs 21.1% [14.0-
28.2]; difference between groups 19.9% [9.1-30.7], p=0.0003, Z test) (10). These impressive 
results may be strong enough to soon warrant the first regulatory approval of in vivo 
fluorescence imaging in oncology.  
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Fig. 2 Illustration of excitation (grey line) and emission (black line) spectra of tissues containing the target 
fluorophore protoporphyrin IX which has an absorption peak at 410 nm and characteristic emission peaks 
at 635 and 705nm. The dashed line shows the tissue auto fluorescence. 
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More recent research is shifting the focus towards novel fluorescent markers that use 
active targeting strategies. Recent advances in nanotechnology and increasing knowledge of 
genes and proteins associated with cancer has enabled the engineering of nanoparticles that 
comprise a targeting moiety (e.g. antibodies, antibody fragments, peptides) conjugated to a 
fluorescent marker (1, 11-13). These particles hold promise to have an increased, more stable 
spectral intensity and improved tumor specificity compared with passive-targeting 
fluorescent markers.  
In addition to providing information about the presence or absence of disease, as 
was typically the case for passive-targeting markers, active-targeting markers can also yield 
functional information about physiological and molecular processes that relate to the 
invasiveness, progression and treatment response of the disease (13, 14).  
This complementary information, directly available to the clinician during ‘molecular 
diagnostic screening’ or ‘molecular image-guided surgery’, has the potential to improve 
clinical decision making and hence could ultimately improve diagnostic accuracy and 
outcome. To illustrate this, in breast cancer over expression of the human epidermal growth 
factor receptor 2 (HER-2) was shown to be associated with (a) the presence of disease, (b) 
involvement of  auxiliary lymph nodes (c) grade 3 tumors (d) resistance or benefit of specific 
adjuvant treatments and (e) poor prognosis (15). Hence, if it were possible to visualize and 
quantify HER-2 during surgical resection, this information may then be used (a) to enable 
more complete surgical resection, (b) as a decision criterion for lymph node resection, as 
direct assessment of (c) tumor grade and (d) for the rational selection of adjuvant treatments, 
to improve overall prognosis (e). 
For both passive- and active-targeting fluorescent markers the ability to accurately 
quantify the in vivo measured fluorescence is critical (12). This, however, is a major challenge 
as the optically detected signal is influenced by numerous factors other than the 
concentration of the marker (16 , 17-19). The fluorescence signal originates not only from 
the marker, but also from various other fluorescent molecules naturally present in the tissue 
such as elastin, collagen and porphyrins and can cause an unknown and variable amount of 
background autofluorescence (20). The excitation irradiance can vary due to variations in the 
light output of the excitation source and due to variations in the excitation optics, which 
both degrade over time. Geometric factors, such as the topography of the tissue, the 
distance and the angle of the excitation and detection source relative to the tissue surface can 
change the excitation irradiance and thus the fluorescence emission. Tissue optics, i.e. the 
scattering and absorption of both the excitation and the fluorescent light also alter the 
fluorescence signal. For example, visually darker tissues, due to high melanin or blood 
content, can decrease the propagation of both the excitation and fluorescence emission light. 
This is further complicated by the fact that the absorption spectrum of blood depends on 
the oxygenation.  
 
All these factors can contribute to quantification errors. These errors may 
compromise diagnostic accuracy when using markers as PpIX. Using active-targeting 
markers such errors may result in suboptimal functional disease information about the 
disease stage, mechanisms and response to treatment. 
 
Methods that accurately quantify the fluorescence signal, in vivo, are thus much 
needed since these will likely improve diagnostic accuracy and will greatly enhance our ability 
to extricate functional information. However, methods and procedures for fluorescence 
quantification are scarcely available in the literature.  Instruments that can perform methods 
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for quantification, so that they can be experimentally tested and validated, are largely 
unavailable. This leads us to the objectives of this thesis. 
 
Objectives 
 
Primary, investigation of existing and novel methods that allow accurate in vivo quantification 
of both passive- as well as active-targeting fluorescent markers in real-time. These should in 
particular be applicable to, i) diagnostic screening for detection of early cancers or,  ii) image-
guided surgery for the resection of cancer margins.  
 
Secondary, validation of such methods through modeling studies and experiments in tissue 
equivalent phantoms and via in vivo studies in preclinical models. 
 
Tertiary, investigation of the clinical feasibility of using fluorescence quantification methods 
in patients during clinical pilot studies.  
 
Outline of this thesis 
 
Chapter 2 describes the optical design and construction of a prototype quantitative 
fluorescence imaging system. The dependence on optical properties was evaluated in 
phantoms. The dependency of tissue color was assessed using pigmented moles of human 
volunteers that received topical ALA administration on the skin.  
Chapter 3 describes the use of this prototype in a clinical trial with patients whom 
had Cervical Intraepithelial Neoplasia (CIN) using topically applied ALA. The purpose of 
this experiment was 1) to investigate the feasibility of CIN detection, and 2) differentiating 
between the different CIN grades.  
Chapter 4 describes the use of fluorescence imaging to guide the surgical resection 
of brain tumors in a preclinical model.  Resection of the tumor under white light was 
compared to resection under fluorescence guidance.   
Chapter 5 discusses the limitations of fluorescence guided resection and describes a 
possible solution that comprises the combination of fluorescence guided resection followed 
by low dose photodynamic therapy over prolonged periods of time. An approach to 
prolonged light delivery was developed and the feasibility of such treatment strategy was 
verified in a preclinical model.  
In Chapter 6 we mathematically evaluated quantitative fluorescence imaging 
methods available in the literature with the purpose to identify methods with optimum 
capability to quantify active-targeting fluorescent markers. 
In Chapter 7 a ratiometric quantification method is introduced. Through 
mathematical modeling the performance was evaluated. Experimentally the performance was 
evaluated in optical phantoms employing a prototype imaging system. The clinical feasibility 
of real-time, image-guided surgery was demonstrated in patients undergoing prostatectomy.  
In Chapter 8 we present the summary and Chapter 9 is a general discussion of the 
current status of of in vivo fluorescence imaging, how this thesis has contributed to this field 
and where the field is moving to. 
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Abstract 
We developed a fluorescence imaging device for the detection of superficial cancer based 
on the Double Ratio technique. In practical use this device resembles an operation microscope 
and can be used in a clinical environment. This device acquires 4 different fluorescence images 
excited at two wavelengths and detected at two wavelengths. From these images it calculates, 
displays and stores Double Ratio images at a maximum speed of 1Hz. The Double Ratio image 
gives the distribution of the fluorophore amount present in tissue and is not affected by local 
variations in tissue optics, i.e. tissue absorption and tissue scattering. The validity of the 
technique was confirmed here by ex vivo tissue equivalent phantom experiments using 
hematoporphyrin and in vivo experiments on normal pigmented moles on  Caucasian human 
skin using δ-aminolevulinic acid induced protoporhyrin IX.  
 
 
Introduction 
 
Early (pre)cancerous lesions are often hard to find under white light illumination. The 
medical community is searching for new non-invasive methods to detect these  lesions, 
which often start in the epithelial layer up to a few hundred micrometers below the tissue 
surface. Fluorescence imaging is an upcoming  non-invasive optical technique that produces 
in vivo images with information of these first few hundred micrometers. The interest of 
research groups (1;2), the investments of various companies like Karl Storz Gmbh. & Co. 
and  Xillix Technologies Corp.,  in combination with recent promising clinical trials (3-8), 
demonstrate the potential of this technique. In this paper we introduce a new fluorescence 
imaging device, which may provide diagnostic information about tissue in addition to that 
offered by currently available fluorescence imaging techniques. 
Various approaches are currently under investigation for in vivo fluorescence imaging. Some 
techniques use fluorophores which are naturally present in the tissue, assuming differences in 
fluorophore content in normal and cancerous tissue (9). Other techniques are based on 
administration of tumor localising fluorescent drugs to enhance fluorescence contrast (10). 
Here background fluorescence of natural tissue fluorophores biases the measurement and 
can be considered an artefact. Using  two excitation wavelengths allows subtraction of this 
background fluorescence (11). Detecting the fluorescence at two wavelengths allows a 
fluorescence measurement relative to a background (12). Algorithms that are based on 
multiple excitation and detection wavelengths are also used to optimise contrast between 
normal and cancerous tissue (13). Some of these methods are successful in specific medical 
fields, nevertheless, the measured fluorescence signal is influenced by factors which may not 
be directly related to (pre)malignancy. Factors like spatial variation in natural tissue 
fluorescence, geometry, variations in excitation fluence, tissue colour and tissue scattering 
may seriously limit the reliability of fluorescence diagnosis (14). 
 
Attempting to avoid these limitations Sinaasappel and Sterenborg developed the Double 
Ratio fluorescence imaging technique (15). This technique aims to detect a tumor localising 
fluorophore, where the Double Ratio image gives the  distribution of the fluorophore 
amount present in tissue. In theory, this technique corrects for variations in natural tissue 
fluorescence, geometry and excitation fluence. Most important, the Double Ratio technique 
also corrects for spatial variations in tissue optics, i.e. tissue absorption and tissue scattering. 
This was confirmed earlier by in vitro and in vivo point measurement experiments (15;16). 
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With these unique and useful correcting properties Double Ratio imaging may provide 
diagnostic information in addition to currently available fluorescence imaging methods. 
 
In this paper we describe a Double Ratio fluorescence imaging device. First we briefly 
explain the fundamentals on which the imaging technique is based, followed by a description 
of the prototype design and construction. Finally the dependence on tissue optics was 
investigated by ex vivo experiments on tissue equivalent phantoms and in vivo experiments on 
human moles. 
 
 
Materials and Methods 
 
The measurement principle 
The Double Ratio technique is based on the acquisition of 4 fluorescence signals. 
Sinaasappel and Sterenborg defined the Double Ratio as (15): 
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Where the constants A and H stand for the fluorescence yield of the reference- and target 
fluorophore, respectively, and the parameters Cr and Ct stand, for the concentration of the 
reference- and the target fluorophore, respectively. 
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Fig. 1: The relation between the Double Ratio and target fluorophore concentration (Ct). 
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The parameters a and b are material constants and thus the Double Ratio varies with target 
fluorophore amount only. Artefacts caused by absorption, scattering, variations in natural 
tissue fluorescence, excitation fluence and geometry are all cancelled out (15). Later work 
revealed that the Double Ratio, besides ‘target fluorophore’ concentration, also has a 
dependency on the fluorescent layer thickness. (17). The relation between the Double Ratio 
and target fluorophore concentration Ct is described by eq. 2 and plotted in fig. 1. The initial 
slope of the curve equals a minus b and the curve approaches the asymptotic value of  a/b 
for high target fluorophore concentrations. For maximum sensitivity to changes in 
fluorophore amount the difference between a and b is preferably as large as possible. This 
can be obtained by choosing both excitation wavelengths to have a: 1.) maximum difference 
in fluorescence yield for the target fluorophore and, 2.) a minimum difference in 
fluorescence yield for the reference fluorophore, see Eq. 2. The Double Ratio measurement 
technique can be adapted for any kind of ‘target fluorophore’. In principle the approach can 
also be employed for other types of spectroscopic techniques such as Raman scattering. 
Prerequisites are sufficiently different excitation spectra for the target and reference 
fluorophore, and the selection of appropriate excitation and detection wavelengths. The 
derivation of Eq. 2 and the underlying assumptions are summarised in the appendix. 
 
Imaging system  
A novel fluorescence imaging system has been developed and built, according to the 
Double Ratio technique. A diagram of the system is shown in fig.2. The output beam of  a 
lamp (Ushio, 200W, XeHg) is split in two by a beam splitter. 
 
Fig. 2 Overview of the Double Ratio imaging system which can acquire 4 fluorescence images excited at 2 
wavelengths and detected at 2 wavelengths. Four images are focused  on one CCD chip. Two wavelength 
detection is then realised by covering each half of the CCD with a filter. Two wavelength excitation is 
accomplished with an alternating light source. Excitation and image acquisition is synchronised with 
choppers. Excitation unit: 1.) 200W XeHg lamp, 2. Lens, 3. Beam splitter, 4. Mirror, 5. Excitation filter 
i, 6. Excitation filter j, 7.  Lenses, 8. Chopper (master), 9. Liquid light guides. Detection unit: 10. Tissue, 
11. First lens, 12. Chopper (slave), 13. Detection filter t, 14. Detection filter r, 15. Second lens, 16. CCD 
chip. Processing unit: 17. PC, 18. Display  
 
The two beams are separately guided through excitation filters, a chopper (EG&G, 651-1E) 
and focussed into two meter long liquid light guides with a core diameter of 8 mm for  
illumination of the target area. Fluorescence light from the target area is collected by a first 
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lens. By exchanging the first lenses the camera magnification can be changed, with a focal 
distance of 10cm or 30cm the detection area is either 1x1cm or 3x3cm. For the longest focal 
length the excitation power is in the range of a few hundred micro Watts per square 
centimetre. Excitation and detection filters as well as cameras can be changed easily. 
Fluorescence emitted from the tissue is detected through two detection filters, covering the 
vertical halves of the CCD chip. Dedicated optics focus four equal images on this single chip 
A slave chopper (EG&G, 651-1E) in the camera unit is synchronised with the chopper in 
the lamp unit. The slave chopper alternates between the horizontal halves of the CCD. A 
figure of the illumination phases is shown in fig. 3.  
 
Fig. 3 Acquisition of four equal images with two 
wavelength excitation and two wavelength detection is 
performed within 2  illumination phases of the CCD 
chip: 1) A detection phase with excitation wavelength  
λi. Here two wavelength detection of Fi,t and Fi,r takes 
place on the upper half of the CCD through the reference 
(λr) and target detection filter (λt). 2) A detection phase 
with excitation wavelength λj Here a two wavelength 
detection of Fj,r and Fj,t takes place on the lower half of 
the CCD through the reference (λr) and target (λt) 
detection filter.  
Excitation Detection 
     covered by chopper 
      not covered by chopper 
1.)  λi 
 
 λj
 λt    λr 
 λt    λr 
2.)  λi 
 
 λj
 λt    λr 
 λt    λr 
 
This prototype allows us to acquire four equal 
images excited at two wavelengths and detected 
at two wavelengths. The chopping frequency is 
chosen to be much higher than the frame rate of the camera i.e. a rate of 1200 Hz. This 
enables the camera to run with a frequency independent of the chopping procedure. In this 
way we are able to use a wide range of cameras. In our experiments two different types of 
cameras are used. A high speed slow scan 14 bit cooled monochrome CCD camera, Proscan 
HSS 1024, with 1024x1024 pixels and a PCI interface. The second camera is a Philips IP 
800, a two step intensified video camera. At maximum gain this camera has a sensitivity of 
5µlux. Interface is a Data translation DT3152 frame grabber. With dedicated software, 
Interactive Data Language (IDL), the four separate spectral images are extracted and Double 
Ratio images are calculated, exactly overlaying and dividing the 4 images pixel by pixel 
according to Eq. 2. Finally, Double Ratio images are displayed at a maximum speed of 1Hz. 
This system allows to image a wide variety of fluorophores and different tissue types. In 
practical use the system resembles an operating microscope and can be used in a clinical 
environment. 
 
Experiments 
In theory Double Ratio values are independent on tissue optics, i.e. the scattering 
coefficient (μs) and absorption coefficient (μa). To check whether our prototype functions 
accordingly we performed two experiments: 1.) An ex vivo tissue equivalent phantom study 
and, 2.) an in vivo study of normal human pigmented moles on normal Caucasian skin. For 
these 2 experiments we used porphyrins as ‘target’ fluorophore. The chosen excitation 
wavelengths band pass filters are: λi: 405nm, (Oriel 56541) and λj: 435nm, (Oriel 56551). 
Detection band pass filters for the ‘reference fluorophore’ are: λr: 550nm , (Omega optical 
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550RDF42) and for the ‘target fluorophore’ λt: 675nm , (Omega optical 675DF110), see fig. 
2. To eliminate any excitation light to enter the camera a long pass filter is positioned in 
front of the first lens (Schott KV500), not in fig. 2. A figure of the Double Ratio calculation 
with these filters is shown in fig. 4.   
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Fig. 4 Graphic presentation of the fluorescence signals needed to calculate a Double ratio. Shown are two 
schematic fluorescence spectra of tissue with porphyrin. One spectum is  excited at 405nm and the other is 
excited at 435nm. The grey areas indicate the fluorescence signals in the appropriate wavelength bands needed 
to calculate a Double Ratio. 
 
Tissue equivalent phantom study 
Tissue equivalent phantom studies have been performed to investigate the sensitivity 
of the Double Ratio images to changes in the absorption coefficient μa and scattering 
coefficient μs. Aqueous solutions were prepared with varying concentrations Intralipid10% 
as a scattering component and Evans Blue as the absorbing component. To simulate natural 
tissue fluorescence we used fluorecein as ‘reference fluorophore’. Hematoporphyrin (Hp) 
was used as ‘target fluorophore’. Before adding Hp to the phantom it was pre-diluted in a 
small amount of acetone to enhance solubility in water. Five different phantoms were made 
in total. The range of optical properties that was used is listed in table 1. Double Ratio 
imaging took place for each phantom while varying the Hp concentration. 
 
Table 1 The optical properties of the tissue equivalent phantoms at 635nm. Phantom 4 aims 
to simulate human skin, while phantom 5 aims to simulates human liver (18). 
 
Phantom μ’s [cm-1 ] μa [cm-1] 
1 4 2.8 
2 30 2.8 
3 4 4.2 
4 49 1.8 
5 62 2.3 
 
Human mole study 
Previous studies have shown that high absorption of dark coloured lesions on a less 
absorbing light coloured skin can cause biased fluorescence measurements (14). To study 
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how our prototype deals with these absorption artefacts in vivo we studied normal pigmented 
moles on Caucasian skin, comparing  the Single Ratio introduced  by Profio to correct for 
background fluorescence (12) with Double Ratios. Here, the Single Ratio is the 
protoporphyrin IX fluorescence detected in the red, divided by the natural tissue 
fluorescence, detected in the green, both excited at 405nm.The measurements were 
performed on two volunteers on which we selected two pigmented moles each. Topical 
administration with a solution of 20% δ-ALA in Instillagel took place. The gel was applied 
on the pigmented mole and surrounding light coloured skin and was held into position with 
Tegaderm. Through metabolic reactions in the tissue δ-ALA is converted to the ‘target 
fluorophore’ Protoporphyrin IX. After half an hour the Tegaderm was removed and the 
skin was cleaned with a gauze. Two hours later Double Ratio images were taken. 
 
 
Results 
 
Tissue equivalent phantom study 
Fig. 5 shows the Double Ratio values versus Hp concentration for the five phantoms. 
The graph shows five similar measured curves close to curve predicted by Eq. 2. There is a 
good correlation between the measured values and the theoretically predicted curve given by 
Eq. 2, which is plotted in the graph as well. A correlation coefficient of 0.98 was found. 
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Fig. 5 Hp concentration versus Double Ratio for five different phantoms (see Table 1.). Although these 
phantoms have different absorbing and scattering properties similar Double Ratio values were found close to 
the curve predicted by Eq. 2. A correlation coefficient of 0.98 was calculated between theory and 
measurement.  
 
Human mole study 
Fig. 6a shows natural tissue fluorescence image of a clinically benign pigmented mole 
on normal light coloured skin at 550nm. Throughout the whole image hairs are visible and a 
v-mark was drawn on the skin for easy recognition of the lesion. Obvious are the higher 
absorption at the location of the mole and the marking. Figure 6b shows the 
protoporphyrinIX fluorescence devided by the natural tissue fluorescence ratio of this mole. 
The normal lesion and v-mark show a clearly higher ratio in comparison with the normal 
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surrounding tissue, illustrating the fact that green light is absorbed stronger than red light in 
these mole and v-mark, which biases this ratio. Fig. 6c shows the Double Ratio image. Both 
the normal mole and v-mark have nearly disappeared which is an indication that they have 
similar porphyrin concentrations in comparison with the surrounding tissue. The v-mark 
and hairs have not completely disappeared but are still slightly visible. This is caused by non 
exact overlay of the four images. We found similar results in all 4 moles. 
 
 
Fig. 6 Fluorescence images of a normal dark coloured mole on a normal light coloured skin after application 
of 5-ALA. We drew a  v-mark on the skin for easy recognition. (a) Natural tissue fluorescence image 
(550nm). (b) protoporphyrinIX fluorescence image (675nm) divided by the natural fluorescence ratio image 
(550nm) here we see  biased elevated values at the position of the v-mark and mole due to a stronger 
absorption in the green  in comparison with the red. (c) Double ratio image with similar values for mole, v-
mark and skin, indicating similar protoporphyrinIX levels for mole, v-mark and surrounding skin.  
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Appendix: Derivation of the Double Ratio 
 
Fluorescence emerging at the surface of a semi-infinite medion is described by: 
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The Double Ratio is defined as: 
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To simplify this expression we make a number of reasonable assumptions. First we assume 
(sufficiently) very shallow penetration of the excitation light. As a consequence, lateral 
diffusion of excitation light can be ignored and only the superficial concentration of the 
fluorophore plays a role. Hence we can write: 
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Note that the escape function now contains two surface vectors; it has become equal to the 
point spread function.  
 
Second, we assume that it is not useful to consider variations in fluorophore distrubution on 
a scale smaller than what the imaging system can resolve. As the point spread function 
defines the limit for the sharpness of the fluorescence image we assume: 
 ( ) ( ) ( ) ( ) ( ) ( )
elswhere                         
  around for    x,s  x,s 
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Now we can write: 
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Putting this back into the Double Ratio we obtain: 
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Gives us a simple expression for the Double Ratio as function of the target fluorophore: 
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i.e. the maximum double ratio that can be obtained is roughly equal to the ratio of the 
excitation coefficients of the target fluorophore. 
 
Note that the DR is not proportional to the concentration. It is sometimes convenient to 
present a quantity that is proportional to the concentration of the target fluorophore. This 
can be done in case good estimates of d and a/b are available: 
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Abstract 
A clinical pilot study was performed to evaluate a new fluorescence imaging technique for 
diagnosing cervical intraepithelial neoplasia. The fluorescence imaging prototype performed 
quantitative imaging of PpIX induced by topically applied ALA using Double Ratio (DR) 
fluorescence imaging technique developed in our group. In total 38 patients entered the 
protocol, 16 were colposcopically selected for biopsy. Of these 16 patients fluorescence images 
were taken and 19 sites were biopsied and the disease was staged histopathologically. DR 
fluorescence imaging of the cervix using our general purpose prototype appeared to be 
cumbersome but feasible. In 4 cases strongly localised fluorescent hotspots were observed at 
the location where the disease was colposcopically visible. In the other cases the fluorescence 
showed a more diffuse multifocal image. The value of the DR determined at the site of biopsy 
correlated in a statistically significant way with the histopathologically determined stage of the 
disease (Spearman rank correlation, r = 0.881, p<0.001 (confidence interval 0.7044 - 
0.9552)). This suggests that non-invasive staging of CIN using this technique is feasible. We 
believe that the results of this study justify the development of a dedicated device that 
combines regular white light colposcopy with DR fluorescence imaging.  
 
 
Introduction  
 
Cervical cancer is the leading cause of mortality in female cancer and the second 
most common cancer in females worldwide (1). The introduction of new screening and 
treatment modalities led to a decrease in mortality of cervical cancer over the last 50 years 
(2,3) However, in the last two decades nation wide screening programs revealed an increase 
in the incidence of cervical cancer. Hornung et al. (4) estimated that the mortality of cervical 
cancer will rise by 20% in the next decade unless improvements are made in the current 
screening and detection techniques. 
Colposcopy has proved to be a useful diagnostic tool in identifying the most atypical 
site for biopsy on the cervix (5, 6). When women with an abnormal Pap-smear are referred 
for colposcopy, diagnosis and treatment of cervical intra-epithelial neoplasia (CIN) requires 
several visits to the doctor. With conventional colposcopy, using acetic-acid staining to select 
the most atypical site for taking a biopsy, only 53.6% of the removed biopsies contain 
histological evidence of a dysplastic process(6). In an overview of fourteen papers, by 
Hopman et al, the positive predictive value of colposcopically directed biopsy was poor for 
‘no CIN’ and increased with increasing stage of the disease (7). Also a considerable inter-
observer variability regarding diagnosing CIN is reported in the literature, for colposcopists 
as well as for histopathologists (8-11).  
 Fluorescence imaging and spectroscopy are relatively new experimental techniques 
for the detection of superficial epithelial changes. Fluorescence diagnostics is based on 
detecting in vivo differences in fluorescence between normal and cancerous tissues. 
Fluorescence is induced by excitation of fluorophores in the tissue, usually with blue or UV 
light. The area of interest is then imaged with a sensitive camera or a point measurement is 
performed with a spectrograph. The shallow penetration of the excitation light makes this 
tool particularly suitable for superficial lesions. Differences in fluorescence between normal 
and cancerous tissue can be naturally present due to different fluorescent molecules in 
normal and cancerous tissue or may lay in different absorption or scattering in tissue 
(7,8,14,15). The use of natural tissue fluorescence spectroscopy for CIN screening was 
extensively evaluated and reviewed by Mitchell et al. They concluded that fluorescence 
spectroscopy performs better than colposcopy (16).  
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Differences in fluorescence between normal and cancerous tissue can also be 
enhanced by administration of a tumor localizing fluorescent drug, preferentially 
accumulating in cancerous cells. Several fluorescent tumor localizers are currently under 
study. 5-Aminolevulinic acid (5ALA) is currently a popular drug for photodynamic therapy. 
When administered topically it diffuses into the cells and converts to the fluorescent 
Protoporphyrin IX (PpIX). Selective accumulation in certain cell types may be caused either 
by differences in cellular enzyme levels, or by differences in the accessibility to ALA (17-20). 
Hillemanns et al used this approach for CIN screening based on fluorescence imaging. He 
showed that fluorescence imaging for CIN screening has similar results compared to 
colposcopy. However by using a more quantitative method, fluorescence spectroscopy with 
a fiber-optic probe at a fixed distance, he found a significant improvement over colposcopy 
(21).  
 Sinaasappel and Sterenborg described a more quantitative method for fluorescence 
measurements, the Double Ratio (DR) measurement technique (22). Two excitation 
wavelengths (λi and λj) and two detection fluorescence wavelength ranges (λm and λn) are 
used to generate four different fluorescence images from which a DR image is calculated. 
The DR algorithm is designed to compensate for tissue color and tissue light scattering and 
produces an image that is dependent on the amount of the fluorescent tumor localizer only 
(23): 
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where Fx,y stands for the fluorescence obtained with excitation wavelength λx detected at 
wavelength λy and C stands for the concentration of the photosensitiser. The parameters α 
and C0 are unknown constants that are related to the fluorescence quantum yields of the 
autofluorophores and of PpIX. It can be shown (23) that α for PpIX in tissue has a value of 
approximately 8. DR is a smooth function of C/C0. At low values of C/C0 it is proportional 
to C/C0 and at higher values it saturates at a value of α.  DR images therefore have a direct 
relation to the PpIX distribution of the imaged area, unbiased by the usual optical artifacts.  
The aim of this clinical pilot study is threefold. First, we will test our general purpose 
fluorescence imaging prototype in a clinical setting. Second, we will evaluate the feasibility of 
using the ALA-DR approach as fluorescence guide for taking biopsies. Third, we will test 
whether this quantitative fluorescence imaging approach is capable of non-invasive staging 
of CIN. 
 
 
Materials & Methods  
 
Patient selection  
Women with an abnormal Pap smear, routinely referred to the clinic for colposcopic 
examination, were asked to participate in this study. Pregnant or lactating women were 
excluded. A total of 30 volunteers enrolled in this study. Ages varied between 19 and 45 
years with a mean age of 30 years. We excluded 6 volunteers with a history of previous 
surgery, causing unknown changes to the epithelium. Another 8 volunteers were 
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colposcopically unsuspect for CIN and consequently no biopsies could be taken. Finally, 19 
biopsies from 16 volunteers were available for our analysis.  
 
Application of ALA  
The ALA was purchased from Medac GmbH (Hamburg Germany) in crystallized 
form. On the day of use it was dissolved in a concentration of 1% (weight/weight) in sterile 
saline solution with the pH adjusted to 5.5 using sodium hydrogen carbonate (21). Sterile 
gauzes drenched with 10ml of this solution were applied to the cervix. The application time 
aimed for was 60 minutes, but in practice ranged from 60-120 minutes. 
 
DR fluorescence imaging prototype  
The DR fluorescence camera is a general purpose prototype developed by our group. 
In practical use it resembles an operating microscope. Preliminary clinical experiments have 
been performed for neurosurgery and dermatology. The device uses two violet wavelengths 
for excitation of the cervix, 405nm and 435nm at intensities of about 100 and 200 μW/cm2, 
respectively. These are not the optimum wavelengths for DR imaging of PpIX, but a 
compromise between contrast and signal to noise ratio. The excitation light is generated with 
a 200 Watt Hg-Xe lamp, two line filters and a chopper alternating the 2 excitation 
wavelengths. Fluorescence of the cervix is detected with an image intensified camera (Philips 
IP 800) through a red and green filter (550nm, bandwidth 42 nm and 675nm, bandwidth 110 
nm). In this manner 4 different fluorescence images are acquired. These are processed into 
DR images by ratioing the two red and green images and subsequently ratioing the two ratio 
images. A detailed description of this imaging device and the theory behind it can be found 
elsewhere (22-24). For focusing and positioning a simple white light (monochrome) imaging 
mode is available. 
 
Procedure  
At the time of colposcopy the moist gauze containing the ALA is removed. Then a 
regular colposcopic procedure is performed, including acetic acid staining and photographic 
documentation of the cervix. In case the decision is made to take a biopsy, the position 
where the biopsy will be taken is marked on the photograph (Polaroid) that was taken to 
document the colposcopy procedure. Subsequently, the colposcope is removed and the 
fluorescence imaging device is positioned and focused. Positioning the device took 1-5 
minutes, acquiring the fluorescence images approximately 60 seconds. The resulting DR 
image was not available to the clinician during the procedure. Next, the fluorescence imaging 
device is removed and the colposcope is used to take the biopsy. The biopsy is then 
subjected to standard histopathological evaluation. 
 
Data analysis  
There were 2 blind steps in the procedure to avoid bias. First, as mentioned above, 
the clinician has not seen any fluorescence image before the biopsy is taken. Second, the 
results of the histopathologic evaluation of the biopsies were not available to us at the time 
of dataprocessing. Defining the location of the biopsy site in the DR image was not simple 
as it involved matching two different images taken with different devices (i.e. the colposcope 
and the fluorescence imaging device). The outcome of this procedure might be biased.  
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Results 
 
General 
Although the prototype functioned properly in the technical sense, its use in this 
particular clinical field proved to be very cumbersome. Especially positioning and focusing 
the device was difficult and time consuming. A typical example of a set of images is given in 
figure 1b. The speculum, visible on the right side of the white light image, often caused 
severe artifacts in the fluorescence image that were not easy to avoid. These artifacts were 
related to reflections of excitation and fluorescence light on the stainless steel surface that 
were not completely blocked by the detection filters. In addition, the wall of the vagina (as 
far as it was not covered by the speculum) was out-of-focus and usually fluoresced intensely. 
In the fluorescence image this area is painted black, so only the fluorescence on the cervix 
remains visible. DR fluorescence images were taken in 16 patients, on whom a total number 
of 19 biopsies were obtained resulting in various different stages of CIN (Table 1).  
 
Table 1  The number of biopsies and corresponding CIN stage, as determined by histopathology 
Stage Number 
No CIN 3 
CIN I 7 
CIN II 3 
CIN III 6 
 
DR fluorescence images of no CIN 
Figure 1a shows the white light image and the corresponding DR image of the cervix 
of a patient that was colposcopically diagnosed as no CIN. Although some speckles are 
visible, DR values close to 1 are found throughout the cervix, suggesting a very minimal 
PpIX production. A similar situation is depicted in figure 1b, the main difference being that 
this cervix is severely inflamed. Nevertheless, the DR image shows a uniform low value, 
suggesting low PpIX levels throughout the cervix.  
 
Localization of CIN with DR fluorescence imaging 
In 4 cases a region with clear boundaries could be recognised in the DR image. In all 
4 cases this region matched the location where the biopsy was taken. The 4 lesions that 
showed localised fluorescence were all classified as CIN III. An example of this is shown in 
figure 2a. In the other 15 cases larger areas with unclear boundaries showed elevated DR 
values. An example of a more diffuse fluorescence image is given in figure 2b. In these cases 
the location with the highest DR never coincided with the location where a biopsy was 
taken. 
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a 
 
 
b 
 
Fig. 1 White light image and DR fluorescence images for two cases where clinically no CIN was detected 
and consequently no biopsy was taken. (a) normal cervix, fluorescence intensity is low, although some speckles 
are present. (b) inflamed cervix. The DR values are close to 1, indicating relatively low PpIX levels. 
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a 
b 
Fig. 2 White light images and corresponding fluorescence images of two cases histopathologically confirmed as 
CIN III. The locations where the biopsies were taken are indicated with a square, the ellipse indicates the 
position of the portio in the fluorescence image. In the first case (a) a clearly localised spot is visible in the 
fluorescence image and corresponds to the location where the biopsy was taken. In the second case (b) a more 
diffuse increase in the DR is observed. 
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Staging of CIN with DR fluorescence imaging 
Figure 3 shows the DR value averaged over a 16 by 16 pixel square located at the 
position where the biopsy was taken versus the histopathological stage. Although some 
outliers are clearly present, there appears to be a significant correlation between DR value 
and histopathology (Spearman rank correlation, r = 0.881, p<0.001 (confidence interval 
0.7044 - 0.9552)) 
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Fig. 3 DR value calculated on the location where the biopsy was taken versus the histopathological staging 
performed on the biopsy. Data from 19 biopsies.  
 
 
Discussion 
 
Localization 
Fluorescence images were obtained of a total number of 16 cervices. In 13 of these 
we have histopathological confirmation of intraepithelial neoplasia. In 4 (of these 13) a 
clearly localised lesion was visible in the fluorescence image on a location coinciding with the 
(previously determined) biopsy location. The biopsies from these sites were all classified as 
CIN III. In the other 9 cervices the fluorescence images showed multiple hotspots of 
variable intensity or a more diffuse elevation of the fluorescence DR. This suggests a more 
multifocal nature of the disease in these cases.  
 
Staging 
The strong correlation between the DR value and the histopathological classification 
as shown in figure 3 is quite striking. This might suggest that there is a relation between the 
amount of PpIX accumulating and the stage of the disease. However, we believe that a 
different mechanism is behind this phenomenon. In the derivation of eq.1 a semi-infinite 
homogenous medium with a homogenous PpIX distribution is assumed. The clinical 
situation is obviously a lot more complex; In the case of topically applied ALA on a mucosal 
surface a PpIX containing layer may have a thickness of up to a few hundred micrometer; of 
the order of, or less than the penetration depth of the violet excitation light. Furthermore, an 
epithelial tumor originates from the boundary between the stromal and epithelial layer and 
then progresses towards the top surface, into the monitored tissue volume. This will increase 
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the average porphyrin concentration in this volume. As a consequence, we must seriously 
doubt the validity of the assumption of a semi-infinite homogenous distribution of PpIX.  
To gain more insight in the dependency of the DR on the layered clinical situation, we 
performed Monte Carlo simulations for which we defined a two-layered structure 
representing the epithelial layer and an underlying stromal layer. Both layers were assumed to 
autofluoresce, only the epithelial layer was assumed to produce PpIX fluorescence. 
Fluorescence emerging from the surface was calculated for both excitation and detection 
wavelengths and a DR value was calculated. By performing different simulations with 
various layer thicknesses we could asses the dependency of the DR on layer thickness. The 
input parameters for the calculations were obtained from literature and personal 
measurements. The technique and the methods are described more in detail in appendix I. 
The results of the simulations are depicted in figure 4.  
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Fig. 4 Interrelationships of DR value, CIN grade and layer thickness as predicted by the Monte Carlo 
simulations. 
 
Comparing these results to figure 3 is highly suggestive of linking the stage of the disease to 
the thickness of the tumour. However, the representation of the tumor progression by a 
perfect smooth walled cube is far from the realistic situation. Moreover, the optical 
properties of cervical tissue are not known and the values used in the Monte Carlo 
simulation were a best guess. However, the values and geometrical assumption used for the 
Monte Carlo simulation were used to investigate a concept that may give insight in the the 
correlation between DR and stage of the disease. The validity of this concept does not 
depend on the exact values of the input parameters as long as the relative relations are 
reasonable. 
 
Methodology 
Tracing the location where the biopsy was taken on the fluorescence image was done 
by hand. Two different imaging devices were used and a topographical match between the 
two images was made based on visual cues and landmarks, like the portio and the edge of 
the cervix. Although a ‘double blind’ approach was used in this procedure, it remains the 
Achillisheel of the study. This problem could very simply be avoided by using an integrated 
device; performing both the photographic documentation and the DR imaging through the 
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same optics. Technically this should not be a major problem, and the preliminary results 
obtained in this study certainly warrant such a development. 
 
 
Conclusions 
 
DR fluorescence imaging of ALA induced PpIX of the cervix using our general purpose 
prototype appeared to be feasible. In 4 cases strongly localised fluorescent hotspots were 
observed at the location where clinically the disease was colposcopically visible. In the other 
cases the fluorescence showed a more diffuse multifocal image. The value of the DR 
determined at the site of biopsy correlated in a statistically significant way with the 
histopathologically determined stage of the disease. This suggests that non-invasive staging 
of CIN using this technique is feasible. We believe that the results of this study justify the 
development of a dedicated device that combines regular white light colposcopy with DR 
fluorescence imaging. 
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Appendix I 
 
For the calculations, we adjusted a Monte Carlo program, based on the code of Keijzer et al. 
(25) adapted by Lucassen et al. (26). The program uses a variance reduction method that is 
called survival weighting. The photons are transported through the medium with a certain 
weight. At each interaction, a fraction μa/(μa+μs) of the weight is deposited while the 
remaining fraction continues. The program was adjusted to enable fluorescence imaging 
simulation. First, the distribution of the excitation light is calculated using the source type 
and dimensions and the optical properties of the medium as input parameters. Light that is 
absorbed in the medium is scored in a (z, r) matrix that is used to assign weight to the 
fluorescence sources. A separate input file that contains the distribution of the fluorophores 
is used as source file for calculation of the fluorescent light distribution. The fraction of 
photons that escapes the medium from the top layer within a certain escape angle is scored 
in a matrix.  
Relative fluorescence levels are determined for semi-infinite double layer geometries 
(representing the epithelial layer and the stromal layer) with embedded square geometries 
representing neoplastic areas. For the simulations, the thickness of the neoplastic area that 
originates at the boundary of the two layers was varied. The epithelial layer is first set to 0.5 
mm (4). The 'tumor' progresses from the boundary between the two layers into the top layer 
(figures 5a-d) Some simulations were also performed with increasing thickness of the total 
epithelial layer from 0.5 to 1.3 mm (figures 5d to 5f) according to the findings of Abdul-
Karim et al (27).  
To our knowledge, the optical properties of cervical tissue in the blue light range are not 
known. For the simulations of the excitation light we have chosen an absorption coefficient 
and a scattering coefficient in the range as found by Keijzer et al. (28) of aorta tissue.  
Excitation optical properties: μa: 15 cm-1, μs 400 cm-1.  
Fluorescence optical properties were chosen to be in the range as found by Hornung et 
al.(4):  
Layer 1 : μa: 0.15 cm-1, μs 90 cm-1, g: 0.9, n: 1.37, thickness: 500-1300 μm.   
Layer 2 : μa: 1 cm-1, μs 150 cm-1, g: 0.9, n:1.37 thickness: >5 cm. 
 
 
 
a b c d e f 
 
 
Fig. 5 The different configurations of the top layer with a progressing 'tumor' embedded. 
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In vivo optical imaging of fluorescent markers for detection and guided resection of cancer 
 
 Abstract 
Background and Objectives: Fluorescence image-guided brain tumor resection is 
thought to assist neurosurgeons by visualizing those tumor margins that merge imperceptibly 
into normal brain tissue and, hence, are difficult to identify. We compared resection 
completeness and residual tumor, determined by histopathology, after white light resection 
(WLR) using an operating microscope versus additional fluorescence guided resection (FGR).  
Study Design/Material and Methods: We employed an intracranial VX2 tumor in a preclinical 
rabbit model and a fluorescence imaging/spectroscopy system, exciting and detecting the 
fluorescence of protoporphyrin IX induced endogenously by administering 5-aminolevulininc 
acid (ALA) at 4 h before surgery.  
Results: Using FGR in addition to WLR significantly increased resection completeness 
by a factor 1.4 from 68% ± 38% to 98% ± 3.5%, and decreased the amount of residual 
tumor post resection by a factor 16 from 32% ± 38% to 2.0% ± 3.5% of the initial tumor 
volume.  
Conclusions: Additional FGR increased completeness of resection and enabled more 
consistent resections between cases. 
 
 
Introduction 
 
The treatment of patients with high-grade gliomas remains a major challenge. The 
prognosis for these patients is poor, with a median survival time after diagnosis and 
treatment of less than 1 year (1,2). It has been suggested that the prognosis for these patients 
is linked to the completeness of tumor removal (3-6). A recent (7) study of 416 patients with 
glioblastoma multiforme indicated that resection of 89% of the tumor volume is necessary to 
improve survival, while resection of 98% or more resulted in a significant survival advantage 
of 4.2 months compared with a resection of less than 98%. However, such a high degree of 
tumor resection is often limited by the surgeon’s ability to distinguish residual tumor tissue 
from surrounding brain tissue under conventional white light microscope illumination (8). 
Hence, methods enabling better intraoperative discrimination of viable tumor borders 
should be valuable. 
Fluorescence imaging and spectroscopy using 5-aminolevulinic acid (ALA)-induced 
protoporphyrin IX (PpIX) is a potential technique to enhance contrast of viable tumor 
borders. Although administration of fluorescent markers to enhance contrast of malignant 
gliomas is not new (9-13), marking tumors with ALA is conceptually different from previous 
investigations, since ALA is not itself fluorescent but is metabolized into fluorescent PpIX 
by a number of malignant tumors in situ through enzymes of the heme-biosynthesis pathway 
(14). ALA-PpIX has been used widely, both for fluorescence diagnostics and photodynamic 
therapy (15). It may avoid problems that arise when a fluorescent marker is administered 
directly, such as leakage from the tumor into surrounding normal brain tissue (16). We have 
shown previously (17-20) that ALA-induced PpIX levels in normal brain tissue, especially 
white matter, are very low. Clinical and preclinical studies suggest that the resulting 
selectivity of ALA-PpIX in certain brain tumors (14,18-25) is a result of various factors. The 
low permeability of ALA at the blood-brain barrier (BBB) (26) reduces uptake in normal 
brain, whereas the compromised BBB in certain brain tumors is thought to permit selective 
ALA transport. Different activities of enzymes in the heme pathway have also been 
observed between tumor and normal tissues, which subsequently enable selective production 
of PpIX (27,28).   
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Stummer et al. recently introduced ALA-PpIX fluorescence imaging for intra-
operative detection and resection of residual malignant glioma in 52 patients using an 
operating microscope adapted for fluorescence imaging (8,23). ALA was administered orally 
at a dose of 20 mg/kg at 3 h before induction of anesthesia and subsequent surgery. They 
observed that leaving “solidly fluorescing” tissue unresected had a negative influence on 
survival, whereas the prognosis of patients with residual “vague fluorescence” was not 
significantly different from that of patients in whom all solid fluorescent tissue was 
completely removed. Histologically, solidly fluorescing tissue was characterized mostly by 
coalescent tumor cells, whereas vaguely fluorescing tissue usually represented infiltrating 
tumor of intermediate or low cellular density. However, analysis of tumor biopsy specimens 
revealed infiltrating tumor also to be present beyond vaguely fluorescing tissue portions. 
This is an important study in demonstrating the potential of ALA-PpIX FGR, but is limited 
by the facts that only a single ALA dose and time interval were used and that the assessment 
of the tissue fluorescence was qualitative and subjective. We hypothesize that more 
quantitative fluorescence-based detection will further improve this technique and, therefore, 
we have developed a system for quantitative fluorescence imaging and image-guided point 
fluorescence spectroscopy. We have previously described this instrument and its initial 
demonstration for brain tumor fluorescence imaging in a pilot study in patients undergoing 
Photofrin-photodynamic therapy (12).  
In the present study we have used this system for FGR in an intracranial tumor-
bearing rabbit model, with the primary objective to compare completeness of tumor 
resection and residual tumor volume after white light resection versus additional ALA-PpIX 
fluorescence-guided resection. These values were quantified by histology of resected tissues 
and of the whole brain after resection. As a secondary objective, we determined the tumor-
to-normal ratio in tissues resected under white light as well as in tissues resected under 
fluorescence guidance. These experiments were done using a fixed ALA dose and time 
interval, as a precursor to planned clinical and preclinical glioma resection studies to 
optimize these two factors. 
 
 
Materials and Methods 
 
Optical design of co-axial fluorescence imaging and spectroscopy system 
The fluorescence imaging/spectroscopy system (12) is an optical illumination and 
detection platform specifically designed for open-field surgical procedures (Figure 1). 
Mounted on a suspension arm, this system illuminates the surgical field uniformly across the 
field of view with 405 nm light at 6 mWcm-2, matching the main absorption peak of PpIX.  
The illumination light is integral to the camera and coaxial with the imaging pathway i.e. it is 
a “point and shoot” device. The fluorescence emitted from the tissue is imaged onto a CCD 
camera with 755×484 pixels at 10-bit dynamic range, that is mounted behind a filter wheel 
containing 5 different band pass filters (20nm FWHM) within the spectral range of 480-720 
(Omega, Brattleboro, NJ). These have an OD of > 7 in the blue/UV range to reject the 
excitation light. The total acquisition time for 5 spectral images and a full fluorescence 
emission spectrum is approximately 30 s. To obtain a quantitative fluorescence image 
various image processing algorithms can be performed on these 5 spectral images, which 
also requires approximately 30 s.  Also, the system is capable of white-light imaging using the 
normal operating room lighting, by combining the red, green and blue channels. The 
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405 nm blue  
Excitation light 
to spectrograph 
 CCD camera 
Filter Wheel: 
400nm: blue 
500nm: green 
550nm: yellow 
630nm: red 
720nm: near IR 
Tissue  
FOV  
working distance is 50 cm, which allows the camera head to be positioned while not 
impeding surgical access.  The field of view is 3.3 cm×2.5 cm and the depth of focus is 2 cm, 
adequate for the geometry of open-field 
neurosurgery. The spatial resolution is 0.15 
mm. A spectrograph, integrated with the 
fluorescence imaging system, performs 
non-contact fluorescence spectroscopy 
over a small area (diameter ~ 0.6 mm) 
within the surgical field, at locations 
selected in the image field-of-view by the 
operator. The positioning of the system is 
similar to that of conventional operating 
microscopes with manual suspension 
arms, although more time consuming in 
the present prototype configuration.  
 
 
Tumor propagation and induction 
This study was approved by the 
Animal Care Committee of St. Michael’s 
Hospital, Toronto (ACC512). We elected 
to use rabbits in this first animal study, 
since this allows fairly large tumors (5-
10mm diameter), which simplifies the 
surgical procedures compared to smaller 
animal models. Since there is no glioma 
model in the rabbit, we used the VX2 
carcinoma, which has similarities in its 
growth characteristics to primary brain 
tumors, such as microinvasion, pseudo 
palisading, growth along the blood vessels and in perivascular spaces, and breakdown of the 
blood-brain barrier within the tumor and in brain adjacent to tumor (19). We have reported 
the use of this model previously for studies of ALA-PpIX distribution and photodynamic 
therapy response (18-20). Male SPF New Zealand white rabbits (3.3-3.8 kg) (Charles River, 
Montreal, PQ, Canada) were used to propagate the tumor cell line by injecting a suspension 
of 106 VX2 cells in 1 ml at 3 locations into the left adductor magnus muscle. These animals 
were euthanized 14–25 days post induction by i.v. injection of T61 (Intervet, Whitby, ON, 
Canada). The tumors were approximately 1 cm diameter when harvested and the VX2 cells 
were extracted using a strainer. Subsequently, the cells were counted in phosphate buffered 
saline (PBS) with a haemocytometer and used within 2 h. For intracranial induction the 
animals were anaesthetized with a mixture of 5mg/kg Xylazine (Bayer, Germany) and 
50mg/kg Ketamine (de Wyet-Ayerst, Guelph, ON, Canada) and the site was shaved and 
swabbed with betadine (Purdue Frederick, Pickering, ON, Canada). A 2-3 cm midline 
incision was made, the scalp reflected and the cranium exposed. Using a 1.5 mm diameter 
drill, a burr hole was performed over the right hemisphere, anterior to the coronal suture 
and 5 mm to the right of the bregma, leaving the dura intact. A 100μl Hamilton syringe was 
introduced to a depth of 3 mm beneath the dura and 105 VX2 cells in 50μl PBS were 
Fig. 1 Optical design of the co-axial multi-spectral 
fluorescence imaging and spectroscopy system, the 
bar indicates the field of view (FOV) of the camera: 
details are found in reference 12. 
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inoculated intracerebrally, over a period of 2-3 minutes with low pressure to avoid trauma. 
Bone wax was used to close the burr hole and the incision was then closed with sutures. 
Buprenex (Reckitt & Colman Ltd., Hull, England) was administered subcutaneous for 
analgesia every 8 h for the first 24 h post implantation. Fourteen animals received VX2 cells 
and 3 animals were injected with saline and used as controls. From previous studies, this 
induction procedure results in tumors of 5-10 mm diameter in 2 weeks. 
  
Resection  procedure  
Surgery was performed 14 days post VX2 induction and 4 h post i.v. injection of 20 
mg/kg ALA in hydrochloride form (Levulan, DUSA Pharmaceuticals, Valhalla, NY, USA) as 
a solution in PBS buffered to pH 6.2-6.8. For surgery the animals were brought under 
general anesthesia by subcutaneous Xylazine/Ketamine injection with Buprenex used for 
systemic analgesia. The eyes were lubricated 
with Lacri-Lube (Allergan Inc., Markham, 
ON, Canada) and closed with tape to prevent 
exposure to the operating and blue excitation 
light. The heart rate and oxygen saturation 
were monitored with a pulse oximeter 
(Model 8500V; Nonin Medical, Plymouth, 
MN, USA). The head was fixed in position in 
a sterotaxic frame with a rabbit adapter 
(Model 900; David Kopf Instr., Tujunga, CA, 
USA). The scalp was shaved, betadine was 
applied to the surgical site, which was 
covered with a sterile keyhole drape, and the 
incision site was injected with 1-2 cc of 2% 
Xylocaine (Astra Zeneca, Mississauga, ON, 
Canada). A 2-4 cm incision was made in the 
scalp along the mid-line and held open with a 
self-retaining retractor. A craniotomy was 
performed using a small hand-held 
orthopedic drill of 1.5mm diameter, which 
was continuously cooled with sterile betadine 
saline solution. Gentle suction was used to 
remove irrigating fluid and bone dust. The 
bone flap was gently elevated with a 
periosteal elevator, aiming to keep the entire 
dura intact. Once the bone flap was 
removed, both left and right hemispheres 
were exposed and the dura was cut using 
microsurgery scissors and forceps.  
Fig. 2 Surgical experimental setup showing 1) 
the fluorescence imaging system, 2) the operating 
microscope and 3) the rabbit covered with a sterile 
keyhole drape.  
 
White light resection 
The tumor was located and removed under white light illumination using an 
operating microscope. Bipolar coagulation was used as required. Saline irrigation and suction 
were used to keep the surgical site clean and a micro pituitary forceps with a 2 mm tip to was 
used to remove the tumor tissue. Care was taken to minimize removal of normal brain. WLR 
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was considered complete once no tumor tissue was visible to the neurosurgeon using the 
operating microscope under white light illumination. 
 
Fluorescence guided resection 
Once WLR was completed, point fluorescence spectra and images were acquired in the 
surgical cavity (Figure 2). Since the fluorescence signal is weak, FGR was performed with the 
operating light switched off and the ambient light was subdued. We aimed to resect (and 
save) all fluorescing tissues. FGR was considered complete once the fluorescence intensity 
throughout the surgical cavity had decreased to the background level of the surrounding 
brain. Since all resected tissues were saved for histology, care was taken to remove tissues 
only by biopsy forceps and not by suction. Immediately following completion of tumor 
resection the animals were euthanized by i.v. T61 injection and the whole brain was removed 
intact. White light resected tissues, fluorescence guided resected tissues and whole brain were 
saved in separate, light-tight containers and immediately snap frozen in liquid nitrogen and 
stored until further use at -70°C . 
 
Fluorescence quantification 
In the present study, the full quantitative capabilities of the fluorescence imaging 
system could not be exploited, since the acquisition time and image processing time of 
approximately 60 s allowed the surgical cavity to fill with blood, obstructing the blue 
excitation and red fluorescence light. Hence, we were forced to obtain fluorescence images 
in real-time (30 frames per s), by using only the red fluorescence channel (640nm, 20nm 
FWHM), combined with suction to clear the surgical site of blood. As a result, we obtained 
relatively poor anatomical definition. Also, although the camera gain, integration time, 
excitation power and focal distance were held constant, the fluorescence signal was only 
partially quantitative, since other factors, such as the tissue optical properties, 
autofluorescence and background light, were not determined. 
 
Histopathology and volume calculations 
Serial sections of 5 µm thickness were prepared at 0.5 mm intervals and stained with 
Hematoxylin & Eosin (H&E). Slides were digitized using a stereomicroscope (Model 
MZFLIII; Leica, Germany) with a digital camera (DC300F), using 1-10X objectives. For 
consistency, areas of normal and tumor tissue were delineated by a single investigator (SPC) 
on these low magnification images using Image Pro-Plus software (Media Cybernetics, 
Silverspring, MD, USA), while observing the original slide under a microscope (Optiphot; 
Nikon, Japan) at higher magnifications using 10-40X objectives. This investigator was 
trained by a neuro histopathologist (GMB), who verified the delineated region of tumor and 
normal tissue on every 7th slide. Both investigators were blinded to the resections. Pixel size 
calibration allowed calculation of the cross-sectional area of each region, and the separation 
between sections then enabled the volumes of tumor and normal tissues to be calculated. 
The percentage of residual tumor after white light resection, RTw, after fluorescence 
resection, RTf , and after white light plus fluorescence guided resection, RTw+f, were defined 
as,   
%100*%,100*,%100*
wbfw
wb
fw
wbfw
f
f
wbfw
wbf
w TTT
TRT
TTT
T
RT
TTT
TT
RT ++=++=++
+= +  
, where Tw, Tf, and Twb are, respectively, the tumor volume in the white light resected tissues, 
in the fluorescence resected tissues and in the whole brain at the end of the procedure.  We 
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note that, using blue excitation light and given the known camera sensitivity, the effective 
depth for fluorescence detection below the tissue surface is likely less than 0.5mm (12). 
Hence, in the calculation of Twb we did not include tumor located at a distance more than 
0.5mm away from the surgical cavity. The percentage of tumor resection completeness in the 
whole brain after white light resection, TRCw, fluorescence resection, TRCf, and white light 
plus fluorescence resection, TRCw+f, were defined here as, subsub RTTRC −= %100 . In order 
to compare the completeness of tumor resection completeness after WLR and WLR+FGR, 
we performed 1-sample t-tests on the groups RTw vs. RTw+f  and TRCw vs TRCw+f. 
 
 
Results 
 
White light resection 
Under white light, the tumor appeared greyish white, that was distinct from 
surrounding white matter, often with areas of hemorrhage and cystic necrosis. All the 
abnormal appearing tissue was removed until only normal white matter was observed in the 
tumor bed. In 11 of 14 animals the tumor was visible under white light illumination, whereas 
in 3 animals the tumor was not visible under white light but a small region of fluorescence 
was found and resected. 
 
Figure 3. Example of white light (a, c) and fluorescence (b, d) imaging in VX2 rabbit brain. (a) shows 
the brain surface before resection, with visible, white-appearing VX2 tumor. (b) shows the corresponding 
fluorescence image, where the bulk tumor fluoresces in red. (c) and (d)  show the the surgical cavity after 
WLR. The bone fluoresces in the green, which was used as overlay to provide image orientation. 
bulk tumor 
fluorescence  
 bulk tumor 
3a 
3b 3d 
3c 
residual 
tumor
resection cavity 
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Fluorescence guided resection 
No fluorescence was detected in the 3 non-tumor bearing control animals while 
resecting up to 7 mm beneath the dura, which was deeper than in the tumor-bearing animals. 
False positive fluorescence was consistently observed in choroids plexus and optical nerves. 
PpIX fluorescence was present in all 14 tumor-bearing animals, verified by point 
spectroscopy that showed the characteristic PpIX peaks at 635 and 704 nm. A typical 
fluorescence image is illustrated in Figure 3. In 2 animals fluorescence resection was not 
completed, since the tumor invaded deeply into the brain and complete resection would 
have been fatal.  
 
 
Histopathology and volume calculations 
Typical H&E stained sections are illustrated in Figures 4-8. The morphology of the 
VX2 tumor is seen in Figure 4, showing the invasive characteristics, with the proliferating 
tumor margin showing protrusions, and distant tumor nests extending in the normal brain. 
Figure 5 shows a section of WLR tissue, which is mostly characterized by a high density of 
tumor cell and a region of normal brain adjacent to tumor. Figure 6 illustrates a section of 
FGR tissue, with a small area of infiltrative tumor cells and a larger area of brain adjacent to 
tumor. In 2 of the 14 animals where FGR was incomplete, relatively large volumes of 
residual tumor were present. In 7 other animals, only small volumes of residual tumor were 
found inside the surgical cavity (Figure 7). In the remaining 5 animals no residual tumor 
could be found post FGR. In several animals, sections of the whole brain post FGR revealed 
tumor cells more than 0.5mm away from the surgical cavity and, therefore, beyond the 
detection depth of this device (12) (Figure 8); in some cases tumor invaded the ventricles 
and choroid plexus and extended to the opposite hemisphere. 
Volumes of resected tumor tissue and resected brain adjacent to tumor were 
calculated and the averages and range of values are listed in Table 1. The tumor-to-normal 
ratio of white light resected tissues was calculated for each animal, and gave a mean of 47% 
± 31%, i.e. almost half of the resected tissue was tumor. The corresponding value for FGR 
tissue was 12%±15%. The percentage of tumor resection completeness and residual tumor 
were then calculated and are listed in Table 2 and a scatter plot of the residual tumor is 
shown in figure 9. Using FGR in addition to WLR significantly increased completeness of 
tumor resection by an average factor 1.4, from 68% ± 38% to 98% ± 3.5% (p=0.010), while 
the  residual tumor in the whole brain  decreased by an average factor of 16-fold from 32% 
± 38% to 2.0% ± 3.5% of the total tumor volume (p=0.010). These values include 3 animals 
where the tumor was not visible using white light but had a small region of fluorescence. It 
could be argued that this situation will not occur in patients, and that these animals should 
be excluded. Doing so, gave an increase in completeness of tumor resection  by a factor of 
1.1  from 86% ± 12% to 98% ± 3.8% (p=0.008), and a decrease in residual tumor in  whole 
brain  by an average factor of 7 from 14% ± 12% to 2.0% ± 3.8% (p=0.008). However, 
including these 3 animals in the also supports the hypothesis that more tumor can be 
resected under fluorescence guidance compared with white light visualization alone.  
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Fig. 4-8 (4) Coronal section showing VX2 tumor (T) in the left hemisphere proliferating into the normal 
(N) brain, and distant tumor cell nests. The arrow indicates the same point in each image using a) 1X, b) 
2.5X and c) 20X objectives. The same convention is used also in Figures 5-8.  (5) Section of WLR tissue 
with areas of tumor and normal tissue. (6) Section of FGR tissue with a small area of tumor and a larger 
area of normal brain.(7) the resection cavity after WLR and additional FGR. Small amounts of residual 
tumor were found at the surface of the cavity. These can be considered False Negative for fluorescence 
detection. (8) The resection cavity after WLR and FGR. Here, small amounts of residual tumor were found 
beyond the  surface of the resection cavity, not be detectable by fluorescence imaging, since the effective depth of 
the blue-light excitation below the exposed tissue surface is likely less than 0.5 mm. (12)  
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Discussion 
 
Increased brain tumor resection 
The above results show that fluorescence image-guided resection using ALA-induced 
PpIX enables identification and resection of significantly more tumor than can be achieved 
by white-light resection alone. The high degree of tumor resection completeness achieved 
with WLR + FGR   (98% ± 3.5%) is close to the value of >98% that has been associated 
clinically with improved survival. (7) The very large variance in tumor resection 
completeness by white light, as evidenced in the standard deviation around the mean (68 ± 
38%), is markedly reduced using additional fluorescence guidance (98% ± 3.5%),  even 
although there was a large range of initial tumor sizes and residual tumor after WLR. This 
suggests that fluorescence guidance not only increases completeness of resection, but also 
enables more consistent resections between cases. 
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Fig. 9 Scatter plot of the percentage of residual tumor using WLR only versus WLR + FGR. In 5 
animals no residual tumor was found histologically after WLR + FGR.  
 
Resection of normal brain 
This study differs from other published reports of FGR, in that we saved all resected 
tissues for histology to determine whether normal brain tissue is also removed during FGR. 
We found a significant amount of normal brain adjacent to tumor was also resected. There 
are two main potential explanations for this. The first is that there is detectable ALA-PpIX 
fluorescing normal tissue. This is unlikely, based on previous studies that have shown very 
low ALA-PpIX levels in normal brain tissues with intact blood-brain barrier (17-20,25), even 
at high ALA administered doses. A more likely cause is a scaling artifact as a result of the 
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resection technique, where a micro pituitary forceps with a 2 mm tip was used to resect 
tissues. This is fairly large relative to the tumor size and the rabbit brain, and may have 
resulted in over resection.  This should be much less of a problem in patients, where the 
resection instruments are relatively small compared to the tumor size. Clinically, more 
accurate resection techniques could also be used, such as gentle suction and ultrasonic 
aspiration, which could not be used here because all resected tissues had to be saved for 
histology. Nevertheless, resecting normal brain tissue adjacent to tumor may be hard to 
avoid completely due to tumor infiltration.  
 
Table 1. Mean ± standard deviation and range of resected tissue volumes, the fraction of tumor, and the 
tumor-to-normal ratio for WLR and FGR tissues, based on H&E stained serial sections.  
 
White light resected tissues Fluorescence resected tissues Whole Brain  
Resected 
Volume 
 
 
(mm3) 
Tw
Tumor 
Volume  
 
(mm3) 
T/N 
Ratio 
 
(%) 
Resected 
Volume 
 
 
(mm3) 
Tf 
Tumor 
Volume  
 
(mm3) 
T/N 
Ratio 
(%) 
Twb
Residual 
Tumor 
Volume 
(mm3) 
Mean 72.0 ± 58.6 47.8 ± 45.4 47 ± 31 104.7 ± 101 8.4 ± 12.1 12 ± 15 2.2 ± 6.4 
Range 0.0-176 0.0-162 0-92 5.6-395 1.0-41.6 1-14 0.0-24.4 
 
Table 2. Mean ± standard deviation and range of Tumor Resection Completeness (TRC) and Residual 
Tumor (RT) for respectively white light resection, fluorescence resection and the combination. 
 
Tumor Resection Completeness (%) Residual Tumor (%)  
TRCw TRCf TRCw+f RTw RTf RTw+f
Mean 67.9 ± 38.4 30.1 ± 38.1 98.0 ± 3.5 32.1 ± 38.4 69.9 ± 38.1 2.0 ± 3.5 
Range 0.0-97.8 1.8-99.3 88.6-100.0 2.2-100.0 0.0-98.2 0.0-11.4 
 
Fluorescence quantification 
Based on this study, translating FGR to the clinic will require further investigation 
into the extent of PpIX fluorescence in normal brain tissue (both in absolute terms and 
relative to tissue autofluorescence at the excitation and emission wavelengths) and, hence, 
the extent of normal tissue removal (False Positives).  It will be critical to quantify the 
fluorescence signal in order to minimize 1.) subjective fluorescence image interpretation, 
which could result in inter-observer variations, and, 2.) artifacts due to variations in tissue 
optical properties (e.g. local blood absorption) that may not be related to malignancy (29). In 
the present study, the full quantitative capabilities of the imaging system could not be 
exploited, as explained above, so that we obtained relatively poor anatomical definition and 
the fluorescence signal was only partially quantitative. This is less of a problem in clinical use 
because of the larger resection cavity and more complete hemostasis (12).  
 
Limitations of the FGR technique  
In the majority of animals complete tumor resection was not achieved due to small 
tumor cell nests (2% ± 3.5% of the total tumor volume) in the the surgical cavity that were 
undetectable by fluorescence. These could be considered as False Negatives for this 
particular device, ALA dose and administration time. Also, in some cases where tumor 
invaded beyond the surgical cavity, this would not be detectable by fluorescence imaging of 
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the cavity, since the effective tissue sampling depth of the blue-light excitation below the 
exposed tissue surface is less than 0.5 mm (12). This suggests that 1.) more sensitive 
fluorescence detection could be advantageous, and, 2.) an adjuvant therapy applied post 
resection capable of targeting small tumor nests and invasive tumor, such as photodynamic 
therapy, may be of further benefit, which is the focus of ongoing studies (30,31). 
 
Limitations of the present preclinical study 
Similar to the ALA doses and time interval used in clinical work by Stummer et al 
(8,23), this preclinical study was performed at fixed ALA dose (20mg/kg) and fixed time 
interval (4h) between ALA administration and surgery, which are not necessarily optimal. 
These parameters will likely affect the sensitivity and specificity of the fluorescence detection 
in tumor tissue. High sensitivity is required in order to minimize the residual tumor post 
resection, while high specificity will allow the surgeon to avoid removing excessive amounts 
of normal brain tissue. However, the latter may be less critical, since clinical judgment will 
always prevail in determining if tissue, whether fluorescent or not, can be removed safely.  
Residual tumor was determined accurately in this study since the whole brain was removed, 
cut in serial sections and examined by histology. Clinically, post operative MR images are 
normally used to determine residual tumor. Hence, it will be important to investigate the 
relationship between the fluorescence signal and MR contrast of  residual tumor. We will 
address these issues in future clinical trials by optimizing the ALA dose and administration 
time and investigating the correlation between the fluorescence signal and MR contrast in 
glioma patients. 
 
Future technology development  
In effort to address the above limitations several technological improvements are 
being considered as part of our ongoing work.  More sensitive ccd detectors with higher 
dynamic range have recently become available that use on the chip amplification. Multiple 
detectors could allow simultaneous acquisition of multiple spectral windows, avoiding the 
long acquisition times as is the case with our current filter wheel and a single detector. The 
used excitation irradiance in this study was low (6 mWcm-2). With existing Xenon arc lamps 
and improved optics this can be increased by a factor 10 or more.  An other option to 
increase excitation irradiance is using raster scanning with a relatively high power pencil 
beam (32). Depth resolution could be improved by utilizing longer excitation wavelengths 
and raster scanning, considering both single and multi photon excitation (33), which could 
then allow depth tomography. The fluorescence signal may be further increased by utilizing 
fluorophores and/or nanocrystals selected for high fluorescence yield, which might then be 
labeled to antibodies for tumor selective targeting (34,35).  In terms of quantitation it would 
be advantageous to obtain fluorescence signal that depends only on the local fluorophore 
concentration. Several spectroscopic methods suggested in the literature have been evaluated 
by Sterenborg et al, (29) using multiple excitation and/or detection wavelengths, which could 
also be utilized for imaging. Currently, we are developing fluorescence imaging systems 
considering the above.   
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In vivo optical imaging of fluorescent markers for detection and guided resection of cancer 
 
Abstract 
Fluorescence-guided resection (FGR) and photodynamic therapy (PDT) have previously 
been investigated separately with the objectives, respectively, of increasing the extent of 
tumour resection and of selectively destroying residual tumour post resection. Both techniques 
have demonstrated trends towards improved survival, pre-clinically and clinically. We 
hypothesize that combining these techniques will further delay tumour re-growth. In order to 
demonstrate technical feasibility, we here evaluate fluorescence imaging and PDT treatment 
techniques in a specific intracranial tumour model.  
The model was the VX2 carcinoma grown by injection of tumour cells into the normal 
rabbit brain. An operating microscope was used for white light imaging and a custom-built 
fluorescence imaging system with co-axial excitation and detection was used for FGR.  PDT 
treatment light was applied by intracranially-implanted light emitting diodes (LED). The 
fluorescent photosensitizer used for both FGR and PDT was ALA-induced PpIX. For PDT, ALA 
(100mg/kg) and low light doses (15 and 30J) were administered over extended periods, which 
we refer to as metronomic PDT (mPDT).    
18 tumour bearing rabbits were divided equally into 3 groups: controls (no resection); 
FGR; and FGR followed by mPDT. Histological whole brain sections (H&E stain) showed 
primary and recurrent tumours. No bacteriological infections were found by Gram staining. 
Selective tumour cell death through mPDT-induced apoptosis was demonstrated by TUNEL 
stain. These results demonstrate that the combined treatment is technically feasible and this 
model is a candidate to evaluate it. Further optimization of mPDT treatment parameters 
(drug/light dose rates) is required to improve survival.  
 
 
Introduction 
 
Protoporphyrin IX (PpIX) can be used as both contrast agent for fluorescence-guided 
resection (FGR) (1) and as a photosensitizer for photodynamic therapy (PDT) (2) of brain 
tumours. After systemic administration of 5-aminolevulinic acid (ALA) and suitable time 
interval (typically 2-6h) ALA is selectively metabolized into protoporphyrin IX (PpIX) by 
certain brain tumours (3-10). PpIX is fluorescent, with characteristic red emission peaks at 
635 and 704 nm under UV/blue light excitation. When photoactivated it can also generate 
short-lived cytotoxic free oxygen radicals, namely singlet oxygen (11). Hence, ALA-induced 
PpIX is used for a variety of both photodiagnostic and phototherapeutic applications.  
In particular, PpIX fluorescence has been investigated for detection and image-guided 
resection of brain tumours (1). In a preclinical model, we recently demonstrated that 
fluorescence guided resection (FGR) of brain tumours decreased residual tumour volume by 
a factor 16 compared to white light resection (12), while Stummer et al demonstrated that 
FGR decreased residual tumour in glioma patients and additionally influenced survival (13). 
Extensive clinical (1, 2) and preclinical (5-7) studies with other PDT 
photosensitizers, including hematoporphyrin derivatives, show that PDT can kill brain 
tumours in situ, but at the cost of some damage to normal brain adjacent to tumour (6, 14). 
Using ALA-PpIX pre-clinically in vitro and in vivo we  (6, 7) and others (5) suggest that 
tumour selective cytotoxicity is feasible. In particular tumour-cell apoptosis can be induced 
by low dose ALA-PDT without inducing a necrotic response in tumour or normal brain and 
with negligible apoptotic cell death in the latter (15). However, adequate and selective 
tumour kill likely cannot be achieved in a single treatment, so that it will be  
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necessary to apply the photosensitizer and light at low dose rates over an extended period, a 
regime that we have termed metronomic PDT (mPDT) (16, 17).  
In summary, although both FGR and PDT have, individually, demonstrated 
potential benefit, it is likely that the combination will be more effective than either approach 
alone. It is the objective of the present work to develop and evaluate pre-clinical models and 
techniques required for this, for ultimate translation to clinical trials. 
Hence, in this paper we demonstrate the technical feasibility of the combined 
treatment for the first time in a tumour-bearing animal model. This requires a relevant 
tumour model, a means of photosensitizer delivery and a light source/delivery system for 
low dose-rate photoactivation. This work is an extension of preliminary observations 
reported previously (18, 19).  
 
 
Materials and Methods 
 
Tumour induction and study groups  
This study was approved by the Animal Care Committee of St. Michael’s Hospital, 
Toronto. Rabbits with intracranially-induced VX2 carcinoma were used as the model. We 
recently demonstrated this is a reasonable first model for assessing FGR (12), since it 
provides tumours of reasonable size (5-8mm), which simplifies the technique compared to 
intracranial rat tumour models (18). The VX2 tumour has similarities in growth 
characteristics compared to human malignant gliomas, including microinvasion, pseudo 
palisading, growth along the blood vessels and in perivascular spaces and break down of the 
blood-brain barrier within the tumour and in brain adjacent to tumour (15). However, since 
the VX2 is not a glioma, it may not the optimal model in terms of the biological responses to 
mPDT, as discussed in more detail below. 
Table 1. Study groups, light delivery devices, light/ALA dose, administration time and mPDT frequency. 
 
mPDT Group n FGR mPDT Light
Dose
FGR/mPDT 
ALA dose 
Illum./ 
Admin. 
time 
Device 
(J)* (mg/kg)*
(min/h) 
Freq. 
A 6 - None 0 0/0 0 0 
B 6 + Dummy 0 0/0 0 0 
C1,2 2 + Manual 15 20/100 42 / 5.5 Every other 
day 
C3,4 2 + Sub-cut. 30 20/100 84 / 5 Daily 
C5,6 2 + Backpack 30 20/100 84 / 5 Daily 
* Light and ALA dose is given per treatment.   
The techniques for tumour induction and FGR in this model have previously been 
described in detail (12).  Briefly, tumours were induced in male New Zealand White rabbits 
(3.3-3.8kg, Charles River Canada, Montreal, QC). For this, 2.105 VX2 cells in 50µl phosphate 
buffered saline (PBS) were injected through a burr hole at a depth of 2 mm beneath the dura 
and allowed to grow. 18 of 22 animals survived without complications and were divided 
equally into 3 groups shown in table 1 as A, B  and C. Group A did not undergo FGR nor 
mPDT. Group B underwent FGR followed by LED implant, but PDT was not applied. 
Group C underwent FGR followed by LED implant and received mPDT. All animals were 
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monitored twice daily and sacrificed by i.v. T61 injection (Intervet Canada, Whidby, ON) 
upon the first signs of neurological deficit, manifested as a pronounced head tilt that we 
estimate could not be misssed more than once. Hence, the subjectivity in this observation 
was estimated to be 12 h.  
 
Fluorescence-guided resection and surgical LED implant  
FGR was performed as described previously (12). Briefly, 20mg/kg ALA (Levulan, 
DUSA Pharmaceuticals, Valhalla, NY, US) was diluted in PBS, buffered to pH 6.2-6.8 and 
injected i.v. within 15 min after preparation. Surgery was performed 7 days post VX2 
induction and 4 h post ALA injection. Animals in groups B and C were anesthetized, a 
craniotomy was performed, the bone flap was removed, the dura was cut and subsequently 
the tumour was located with an operating microscope under white light illumination and 
resected by FGR. For this, the surgical 
cavity was illuminated with 405 nm (20 
nm FWHM) light and red PpIX 
fluorescence was detected at 630 nm (20 
nm FWHM, > OD 7 rejection of the 
blue/UV excitation light). The eyes were 
closed with tape during FGR, to prevent 
eye and skin photosensitive reactions. 
Biopsies were taken under FGR, fixed in 
formalin and saved for histopathology. 
Groups B and C received a permanent 
LED implant that was positioned inside 
the surgical cavity (L711SED/H, 
Kingbright, EMX Enterprises Ltd., 
Richmond Hill, ON, Canada). The LED 
was attached to the bone flap through an 
enlarged burr hole, as shown in Fig. 1a. 
To avoid irritation, the electric wires of 
the LED were isolated with medical 
grade silicone. To prevent light exposure 
to the skin, the rear side of the LED was 
covered with black medical grade epoxy. 
Electric wires were connected to a 
power supply in 3 different 
configurations, as described below. 
Hibitane antibiotic cream was applied 
topically on a daily basis to prevent 
irritation and infection. As described 
above, analgesic was administered. 
Steroids (Dexamethasone, Sabex, 
Boucherville, QC, Canada) were 
administered i.m. daily to all animals, 
starting 7 days after tumour induction, 
to decrease intracranial pressure and to 
mimic the clinical situation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  a 
  c
LED 
Timer 
Battery 
  b
Fig. 1 (a) An LED placed into an enlarged burr hole in 
the bone flap. Electric wires were connected to a power 
supply in 3 different configurations. Manually, for this, the 
electric wires in (a) were connected to an external 6V DC 
power supply. (b) Subcutaneously, with an automatic timer 
switch and battery placed on the shoulders, or (c) held in a 
backpack. 
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Drug and light delivery for mPDT 
 
For each mPDT treatment 100mg/kg ALA was prepared and injected as described 
above. mPDT was started the day following FGR. For this, the animals were not 
anaesthetized, but  animals were kept under dim light levels for the entire period after 
tumour resection. The output power of the LED with 5mm diameter was 6 mW when 
supplying a 20mA driving current. We assumed the hemispherical diffuse LED surface to be 
in contact with brian tissue, which translated to an irradiance of approximately 6 mW.cm-2. 
The center wavelength was 635nm (30nm FWHM), verified with a spectrometer. Because of 
the low power a relatively high ALA dose was used, significant bleaching of PpIX was not 
expected based on our previous FGR work where similar power levels were used for 
excitation of fluorescence and bleaching was not observed (12).  The temperature of the 
LED did not exceed 37-39°C. For animals C1,2 the light was delivered every other day by 
manually connecting the LED wires exposed on the outside of the scalp to an external 6V 
DC power supply, delivering 15J over 42 min at 5.5h after  ALA administration. With the 
intention to be less constraining, for animals C3,4 the light  was delivered by a miniature 
automatic timer switch and 6V lithium battery (2CR5MPA/1B, 1400mAh, Panasonic) both 
embedded in medical grade silicone. This timer device was developed for this study and 
comprised a circuit board of three stages, 1.) a timer integrated circuit (IC) (LM556, Texas 
Instruments, TX, US) operating in mono stable mode and generating a square wave clock 
signal as input for the second stage, 2.) a 12 bit binary counter (CD4040, Texas Instruments, 
TX, US), the output of which was fed into 3.) a similar timer IC operating in monostable 
mode to provide the 20mA current for the LED. This device was able to switch on the LED 
daily for 84 min with the above battery.   
In animals C3,4, the timer and battery were placed subcutaneously on the shoulders 
with the electric wires of the LED passed subcutaneously from the skull, delivering 30J over 
84 min once per day at 5h after daily ALA administration. The device shifted sideways 
causing discomfort, so that after two mPDT treatments the timer device and battery were 
surgically removed, but the LED remained in place. To avoid this problem in animals C5,6 a 
similar automatic timer switch and battery were held in a backpack (NP-620076, Harvard 
Apparatus, Saint-Laurent, QC, Canada) shown in Fig. 1c. These were well tolerated by the 
animals.  
 
Histopathology 
After sacrifice the brain was removed intact and fixed in 10% formalin for a 
minimum of 30 days. 5μm thick sections were prepared of the whole brain including the 
tumour regions and stained with hematoxylin and eosin (H&E). Gram stains were also 
performed to investigate the presence of any bacterial infection. Fluorimetric TUNEL 
(terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling) staining was 
performed to investigate the presence of PDT-induced apoptotic cells. This stained the 
DNA of apoptotic cells with green fluorescein fluorescence (Promega, Madison, WI, US), 
while propidium iodine (Molecular probes, Eugene, OR, US) stained all cell nuclei with red 
fluorescence. These were examined simultaneously using a confocal laser-scanning 
microscope (LSM510, Zeiss, Germany) with 488nm excitation and 505-550nm detection for 
fluorescein and 543nm excitation and >585nm detection for propidium iodine.  
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Results  
 
Surgical procedure and metronomic PDT  
Tissue with positive PpIX fluorescence was detected and resected in animals in 
group B and C. Two rabbits did not recover from anesthesia, likely as a result of anesthetic 
overdose. One animal did not 
recover well from surgery,  
demonstrating unresponsive 
behavior and had to be 
sacrificed 4 days post resection. 
1 animal scratched out the LED 
implant and was sacrificed, no 
other animal attempted to do 
so. The remaining 12 animals 
recovered well from tumour 
resection, showing normal 
responsive behavior, motor 
function, bowel output and 
food intake. I.v. ALA injections 
were performed within a ±15 
min window and the timer 
circuits worked successfully 
with an accuracy of ± 3 min.  
 
Survival  
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Figure. 2 Scatter plot with survival times for groups A, B and C. 
A significant difference (p<0.05) was found between groups A and 
B, but not between B and C (p>0.05). 
All surviving animals were sacrificed between 8 and 21 days after tumour induction 
when demonstrating a head tilt. The average survival times were, group A: 13.3 ± 2.9 days , 
B: 17.0 ± 1.4 days and  C: 17.7 ± 2.2 days, as shown in the scatter plot in Fig. 2. Rabbits C1,2 
were sacrificed at 15 and 16 days.  
Rabbits C3,4 were sacrificed at 17 and 19 
days, where, as described above, the 
timer was removed as a result of 
discomfort after two mPDT treatments. 
Rabbits C5,6, in which the backpack was 
used,  were sacrificed at 18 and 21 days.  
An independent-sample t-test 
demonstrated a significant survival 
increase (p<0.05) in group B compared 
to group A, indicating a benefit of 
tumour resection vs no resection. 
Group B and group C showed no 
significant difference (p>0.05), 
indicating that daily mPDT of up to 30J 
and 100mg/kg ALA did not influence 
survival.  
 
 
 
 
 
 
 
 
 
 
Fig. 3 H&E stained coronal section of the rabbit brain 
with the arrow pointing towards a recurrent VX2 tumour 
re-filling the resection cavity previously made by FGR.  
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Histopathology  
H&E stained sections of the biopsies taken during FGR revealed regions of 
infiltrative tumour under microscopy, similar to our previous findings (12). When removing 
the brain in groups A, B and C, the brains were swollen and tumour was visible with the 
naked eye. Coronal sections demonstrated large primary tumours in group A, and large 
recurrent tumours mostly refilling the surgical cavity made with FGR in groups B and C, as 
illustrated in Fig. 3. No necrosis was observed in proximity of the LED position. Gram 
stains were negative for all animals, demonstrating the sterility of the resection and LED 
implant surgical procedures. PDT-induced apoptosis is likely maximum in the 12-24h time 
interval after the last mPDT treatment (20), making it difficult to quantify apoptosis here, 
since most animals were sacrificed at different time points, according to neurological signs: 
C1,2 at 24-48h, C3,4 at > 48h, and C5,6 at 12 and 24h after the last mPDT treatment. TUNEL 
staining of group A (no mPDT) demonstrated only small percentages of apoptosis, in the 
range of 1-2% in the tumour, with no detectable apoptosis in the contra lateral normal brain. 
Similar results were found for animals C1-4. By contrast, some sections of animals C5,6 
demonstrated areas with a higher amounts of tumour-selective apoptosis, in particular the 
animal sacrificed at 12h post mPDT, as is shown in Fig. 4a. Note that the apoptosis is 
selectively present in the tumour and to a much lesser extent in the brain adjacent to tumour. 
The normal contra lateral brain shows no apoptosis as shown in Fig. 4b. H&E staining of 
adjacent sections demonstrated cell shrinkage and pyknosis, which are associated with 
apoptotic cells, at similar locations and rates of incidence (21).  
 
 
 
 
 
 
 
 
 
 
 
 
T 
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Fig. 4 Fluorescence confocal microscopy image (10x objective, NA 0.5) of fluorimetric TUNEL assay of 
rabbit brain sections. (a) The infiltrative tumour margin (T) and normal brain (N) 12h after 14 daily mPDT 
treatments. TUNEL positive (apoptotic) cells are stained green and all cells nuclei are labelled red (propidium 
iodine). The tumour margin can be identified, since the tumour has a larger nuclear density in comparison with 
the normal brain: arrows point towards the tumour margin (Permission for reproduction was obtained from the 
original publisher (17)). (b) Image of contra lateral normal brain. 
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Discussion 
 
These results demonstrate that a new treatment strategy for malignant gliomas, 
comprising of fluorescence guided resection (FGR) with adjuvant metronomic PDT 
(mPDT) is technically feasible and the intracranial VX2 model in the rabbit is a candidate to 
evaluate this combined treatment. 
Tissue morphology of group B demonstrated recurrent brain tumours approximately 
10 days after FGR, refilling the entire surgical cavity. This is likely the result of small tumour 
nests that were undetected by FGR (12), but that can be detected using high sensitivity 
bioluminescence imaging with luciferace-transfected tumour cells (18). This is similar to 
gliomas, where recurrence is also often within close proximity of the resected margin (22, 
23). This observation further validates the need to follow FGR by an adjuvant therapy such 
as mPDT.  
The presence of apoptotic cell death with high tumour selectivity demonstrates that 
the concept of mPDT is valid in this model. However, FGR followed by mPDT with daily 
light and drug doses of up to 30J and 100mg/kg, for up to 14 days, did not influence 
survival compared to the FGR only group. This indicates further optimization of the mPDT 
treatment parameters (drug/light dose rates and application times) is required to improve 
survival, dose escalation studies are in progress.  
Although the VX2 model has similarities in growth characteristics compared to 
gliomas, as discussed above, it is likely not the optimal tumour model in terms of the 
biological response to mPDT, since it is a carcinoma rather than a glioma. The murine 9L 
gliosarcoma, human U87 glioma or the rat CNS-1 glioma models are more relevant, so that 
we are extending this work to these rat models. Since the rat brain is smaller, this is 
substantially more challenging, both to achieve a high degree of tumour resection by FGR 
and to apply the mPDT light.  
The methods used here to assess tumour response, namely the onset of neurological 
deficit and post mortem histopathology, provide information at only one time point and 
require sacrifice of the animal. It would be preferable to obtain tumour response data over 
multiple time points in single animals. This may be feasible with techniques as MR imaging, 
but this is costly and measures only gross tissue response. As mentioned above, an 
alternative is to use of bioluminescence imaging. We have recently demonstrated the 
feasibility of bioluminescence monitoring of (non-metronomic) PDT response in vivo (24). 
We plan, therefore, to use bioluminescence imaging to monitor completeness of FGR 
resection, tumour re-growth after resection and tumour response to mPDT (18).  
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Abstract 
With the advent of molecular-targeted fluorescent markers there is a renewed interest in 
fluorescence quantification methods that are based on continuous wave excitation and multi-
spectral image acquisition. However, little is known about their in vivo quantification 
performance. We evaluated the performance of five selected methods by, analytically 
describing these and varying the input parameters of, irradiance, excitation geometry, 
collection efficiency, autofluorescence, melanin content, blood volume, blood oxygenation and 
tissue scattering over relevant in vivo ranges, using optical properties resembling human skin. 
We identified one method that corrects for all of the above variations.  This requires image 
acquisition before and after marker administration, under identical geometry. Hence, it is 
suited for applications where the site of interest can be relocated (e.g. anaesthetized animals 
and dermatology). For applications where relocation is not possible, we identified a second 
method where the uncertainty in the fluorescence signal was ±20%. Hence, use of these 
methods can substantially aid in vivo fluorescence quantification over use of the raw 
fluorescence signal as this changed by more than 3 orders of magnitude. Since these methods 
can be computed in real-time, they are of particular interest for applications where direct 
feedback is critical, as diagnostic screening or image-guided surgery. 
  
 
Introduction  
 
“Early detection (of cancer) is and will continue to be, the single best way to 
significantly improve therapeutic outcomes.” (1). One approach that can enhance the 
capability of the physician to visualize early cancers is the administration of a tumor- 
selective fluorescent marker. The tissue can then be illuminated with light of an appropriate 
wavelength to excite the marker and the resulting fluorescence can be detected using a 
sensitive camera. This principle has been under investigation for the detection of various 
malignancies using either fluorescent markers or autofluorescence, for over 2 decades (2-4). 
In most applications the diagnostic accuracy obtained has been quite variable. This was 
mainly due to low fluorescence contrast between normal and tumor tissue, caused by non-
specific uptake of more traditional fluorescent markers as fluorescein (5) and Photofrin™ 
(6). These relied on rather passive targeting strategies and generally depended on differences 
between the vasculature or pharmacokinetics of tumor vs. normal tissues.  
More recent research is shifting the focus towards novel fluorescent markers that use 
active targeting strategies. Recent advances in nanotechnology and increasing knowledge of 
genes and proteins associated with cancers has enabled the engineering of nanoparticles that 
comprise a targeting moiety (e.g. antibodies, antibody fragments, peptides) conjugated to a 
fluorescent marker (1, 7-9). These particles hold promise to have an increased, more stable 
spectral intensity and improved tumor specificity compared with passively-targeting 
fluorescent markers.  
In addition to providing information about the presence or absence of disease, as 
was typically the case for passively-targeted markers, actively-targeted markers can also yield 
functional information about physiological and molecular processes that relate to the 
invasiveness, progression and treatment response of the disease (9, 10). This complementary 
functional information directly available to the clinician in vivo, during diagnostic screening or 
surgery could improve clinical decision making may therefore ultimately improve therapeutic 
outcomes.  
The ability to accurately quantify the in vivo measured marker fluorescence is critical 
to unravel functional disease information (1, 8). This is a major challenge since the 
fluorescence measured in vivo depends on many parameters other than the concentration of 
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the fluorescent marker, including the tissue autofluorescence, tissue-detector geometry and 
the absorbing and scattering properties of the tissue, which can contribute to quantification 
errors (11).  
Several quantification techniques have been suggested employing either pulsed (12), 
modulated (13) or continuous wave (CW) excitation. Here we focus on the latter, as 
explained below.  
Using CW excitation and tunable filters hyper spectral “data cubes” can be 
generated. With a priori knowledge of the fluorescent molecules that are present and using 
appropriate spectral unmixing algorithms the individual contribution of each can be 
determined (14, 15). Much progress has been made on the development of image 
reconstruction algorithms and instrumentation for fluorescence tomography using CW 
excitation(7). Fluorescent marker quantification by tomography has been validated in 
phantoms as well as in vivo in small animal models (16, 17).  
However, the clinical utility of both hyper-spectral imaging and tomography is 
limited in applications where real-time feedback (~≥30 frames/sec) is required, as in 
endoscopic screening and image-guided surgery. Such high frame rates are currently difficult 
to achieve due to the complexity of image acquisition and processing (14, 18). 
Tomographic 3-D information is not required per se for endoscopic applications nor, 
in most cases, for image-guided surgery, since early tumors arise, relatively superficially, in 
intra-epithelial layers at depths of a few hundred microns (19), while  tumor surfaces are 
exposed during surgical resection. Hence, for these applications, 2-D quantification methods 
can be used.  One approach is to employ multi spectral (rather than hyper-spectral) images, 
acquired in a few wavelength bands, combined with image processing algorithms that use 
combinations of subtractions and ratios. Due to their relative simplicity, real-time 
computation and display is feasible. Several of these approaches were first suggested in the 
literature around 20 years ago. With the advent of novel fluorescent molecular markers there 
is a renewed interest in these methods because of their apparent effectiveness and simplicity.  
For example, in 1984 Profio et al. calculated the ratio of marker signal over the reference 
autofluorescence signal (20). This approach was recently used by Nakayama et al.  for 
quantification of blood perfusion in brown adipose tissues of mice, using the near-infrared 
marker indocyanine IR-786 (21), and was modified by Kircher et al. who instead of using the 
autofluorescence, used a second cyanine marker as reference, for quantification of enzyme 
activity (22, 23). Further, a subtraction method described in 1987 by Baumgartner et al. (24) 
is now commercially available on a widely used (25) small animal fluorescence imaging 
system (IVIS®, Xenogen® Corp., Alameda, CA) to subtract the organ-specific 
autofluorescence (26).  In addition to these several other methods have also been described 
(27-29).  
Thus, although some of these methods are in active use today, little is known about 
their actual in vivo quantification performance. The objective of the present work was, to 
evaluate the performance of a selection of methods available in the literature through 
mathematical modeling. We described the fluorescence signals by closed-form, analytical 
solutions to the diffusion equation. The quantification performance was then evaluated by 
varying each of the input parameters of irradiance, excitation geometry, collection efficiency, 
autofluorescence, melanin content, blood content, blood oxygenation and tissue scattering 
over ranges that can be expected during in vivo imaging around a standard set of optical 
properties that resemble human skin.  
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Figure 1. (a) Modeled excitation (grey) and emission (black) spectra of tissues containing the fluorescent 
marker protoporphyrin IX, which has an absorption peak at 410nm and characteristic emission peaks at 
635 and 705nm. This is based on previous measurements in human subjects (38).  The dashed line shows 
the tissue autofluorescence. Schematic representations of the uncorrected fluorescence signal and quantification 
methods are shown in (b-g). 
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Models and Methods  
 
Correction Methods 
Each method is depicted schematically in Fig.1. A porphyrin-like marker was 
selected as the model fluorophore, since the majority of these methods were developed for 
quantification of porphyrins.  However, these methods can easily be adapted to other near-
infrared markers by shifting the excitation and emission wavelengths. The signal output was 
referred to as Qmethod and excitation and emission wavelengths are listed in Table 1. 
 
Table 1. Excitation and emission wavelengths used in the different quantification methods 
Excitation 
λ [nm] 
Emission 
λ [nm] 
Correction 
Method 
Ex1 Ex2 Em1 Em2 Em3 
Uncorrected 405  630   
Profio  et al. 410  690 562  
Baumgartner et al. 405 470 630   
Montan et al. 337  630 488 600 
Sinaasappel et al. 405 435 630 550  
Saarnak et al. 405  652 510  
 
The raw uncorrected fluorescence signal [mW.cm-2], as shown in Fig. 1b, employs a 
single excitation and emission wavelength  and is described as, ( 11 emexdUncorrecte ,FQ )λλ=         1 
Profio et al. used a single excitation and two emission wavelengths, as shown in Fig. 
1c. Here, the ratio was calculated of the red marker plus red autofluorescence over the 
autofluorescence in the green part of the spectrum where the fluorescence yield of the 
marker was negligible. The green autofluorescence was assumed constant and used as a 
reference (20), i.e. (
(
)
)21
11
emex
emex
ofioPr ,F
,F
Q λλ
λλ=          2 
This formalism is also valid for the work described by Nakayama et al. (21) and also that of 
Kircher et al. (23), where the autofluorescence in the denominator was replaced with 
fluorescence from a second marker, for which a second excitation wavelength was used. 
Montan et al. (Fig.1d.) used one excitation and three emission wavelengths (27). The 
red background fluorescence was measured in a narrow spectral region in which there was 
minimal marker fluorescence. This was first subtracted from the red marker plus red 
autofluorescence and then divided by the autofluorescence in the blue-green spectral range,  ( ) (
( )
)
31
3111
emex
emexemex
tanMon ,F
,F,FQ λλ
λλκλλ −=       4 
After administration of the marker, the scaling factor κ was measured with a spectrograph in 
a normal tissue region with assumed negligible marker concentration (Cm = 0) and the 
magnitude of κ was chosen such that both red emission wavelengths yielded the same 
autofluorescence,   ( )
( )31
11
0
emex
emex
)C( ,F
,F
m λλ
λλκ ==          5 
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Baumgartner et al. used two excitation and one emission wavelengths (24). The first 
excitation wavelength was used to excite the marker plus autofluorescence and the second to 
excite mostly autofluorescence, so that this could be subtracted,  ( ) ( 1211 emexemexrBaumgartne ,F,FQ )λλβλλ −=       6 
The excitation irradiances were scaled based on fluorescence imaging, before administration 
of the marker (Cm = 0), such that both excitation wavelengths yielded equal tissue 
autofluorescence,     (
(
)
)12
11
0
emex
emex
)C( ,F
,F
m λλ
λλβ ==          7 
The above formalisms are also valid for the method that was recently described by Xenogen 
Corp. (26).   
Sinaasappel et al. used two excitation and two emission wavelengths (28). Using 
excitation on and off an absorption peak of the marker,  the red marker fluorescence was 
divided by the green autofluorescence (where the marker fluorescence is minimal). 
Subsequently, this red/green ratio was divided by a red/green ratio for the second excitation 
wavelength that was chosen to have low marker fluorescence,   ( )
( )
( )
( )12
22
21
11
emex
emex
emex
emex
lSinaasappe ,F
,F
,F
,FQ λλ
λλ
λλ
λλ ⋅=       8 
Saarnak et al. used one excitation and two emission wavelengths (29). The red marker 
fluorescence was divided by the green autofluorescence, similar to Profio et al. Subsequently, 
this was divided the same red/green ratio measured in tissue prior to marker administration 
(Cm = 0). Unlike the other methods evaluated here, this requires that the images are aquired, 
before and after marker administration on the same tissue site under identical geometry. The 
assumption was then made that the optical properties and autofluorescence may vary 
spatially, but remain constant over the time interval between image acquisitions, 
( )
( ) ( )
( )
( )( )110
210
21
11
emexC
emexC
emex
emex
Saarnak ,F
,F
,F
,FQ
t
t
λλ
λλ
λλ
λλ
=
=⋅         9 
As these methods are based on continous wave excitation they are inherently unable 
to extract information about changes in fluorescence quantum yield or lifetime.   
 
Evaluation of quantification performance 
We evaluated the correction performance of these different methods by 
mathematically describing the fluorescence signal, defining standard input parameters and 
introducing variations around these standard values. For this, one parameter was varied one 
at a time, with the other parameters fixed at their standard value. As a measure of the 
quantification or correction performance we defined the factor CP as the change in the 
corrected signal due to the introduced variations relative to the signal with the standard input 
parameters, 
)dardtans(Q
)ied(varQCP = . For the purposes of inter-comparing the methods, we 
calculated a Signal Change index, SC, as the maximum over the minimum correction 
performance, 
(min)CP
(max)CP
SCparameter = . Here a value of 1.00 indicates perfect correction, 
while larger values indicate imperfections.  Additionally, the total signal change, TSC, was 
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defined as the product of the signal changes due to the individual parameters, at fixed target 
fluorophore concentration. 
 
Mathematical description for fluorescence emission 
The fluorescence generated at the tissue surface was described with analytical 
solutions to the diffusion equation. The formalism applied here was based on the time-
independent, 1-D, broad-beam, homogeneous-medium case, which were correlated with 
Monte Carlo simulations for fluorescence generated at the tissue surface (30). This solution 
was modified by adding dimensionless functions γ and η that describe the influence of 
geometry on the excitation irradiance and the collection efficiency of the photodetector, 
respectively, and have values between 0 and 1.  Further, we represented the fluorophores 
present in tissue as two groups and assumed that their absorption coefficients are 
proportional to the concentration. The first group is the fluorescent maker of interest, 
assumed to have known concentration, Cm [M],  and fluorescence yield, H [cm-1.M-1], at the 
excitation-emmission wavelength pair (λex,λem). H is the product of the fluorescence quantum 
yield and the molar extinction coeficient. The second group, tissue autofluorophores, have 
concentration Ca and fluorescence yield A(λex,λem). Hence, the detected fluorescence signal, 
F(λex,λem) in [mW.cm-2] is given by,  
( ) ( ) ( ) ( )[ ]( ) ( ) ( )[ ] ( ) ( )( ) ( ) ⎥⎥⎦
⎤
⎢⎢⎣
⎡ −⎟⎟⎠
⎞
⎜⎜⎝
⎛
+
+⋅⎥⎥⎦
⎤
⎢⎢⎣
⎡
−
+= 1
8211
8211
22 emefem
extem
emefextem
emexaemexmex
emex D.
'D.
'D
,AC,HCI
,F λμλ
λμλ
λμλμλ
λλλληγλλλ  10 
 The excitation irradiance at excitation wavelength λex [nm] is given by I(λex) [mW.m-2]. 
D(λem) is the optical diffusion coefficient of the tissue at wavelength λem, given by 
, where μ’( ) ( )[ 13 −= emtem 'D λμλ ]
)
t(λem) [cm-1] is the linear attenuation coefficent given by 
. μ’( ) ( ) ( emtotalaemsemt '' λμλμλμ += s(λem)  is the reduced scattering coeficient and μatotal(λem) is 
the absorption coefficient of the  tissue fluorophores (marker plus auto), so that 
( ) ( ) ( )exesfluorophoraextissueaextotala λμλμλμ += . The effective attenuation coefficient μef(λem) is 
given by, ( ) ( ) ( ) ( )[ ]emsemtotalaemtotalaemef ' λμλμλμλμ += 3 . Further, the absorption of the 
tissue was considered much larger than that of the fluorophores (μatissue>>μafluorophores), so that 
μafluorophores was chosen negligible in calculating D(λem),  μ’t(λex) and μef(λem).  
 
Standard values for the input parameters 
The following standard values were assigned, I: 100 mWcm-2,  γ and η: 1.00 [-]. Cm 
and Ca: 0.01 [M]. H(λex,λem), and A(λex,λem) are  listed in Table 2.  Their relative magnitude was 
estimated based on the fluorescence emission spectra shown in Fig. 1a.  
The optical properties of human skin were calculated using the model of Svaasand et 
al, (31) providing average values for the epidermal and dermal layers. Parameters that 
dominate the absorption of human skin, μaskin [cm-1] in the visible to near-infrared wavelength 
range are blood volume (B), blood oxygenation (StO2) and melanin content (M),  
unpigm
a
melanin
a
blood
a
skin
a )M,()StO,B,()M,StO,B,( μλμλμλμ ++= 22   11 
, where μablood is the absorption coefficient of blood,  ( ) ( )[ ]λμλμλμ HbaHbOablooda ).StO(StOB)StO,B,( 2222 1−+⋅=    12 
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B was assigned a standard value of 1% (31). StO2 = 100% (32). The absorption coefficients 
for oxygenated, μaHbO2(λ), and de-oxygenated, μaHb(λ), hemoglobin were also obtained from 
literature values (33). The absorption coefficient of melanin μamelanin was calculated by,  
4694
⎥⎦
⎤⎢⎣
⎡= λλμ M)M,(
melanin
a         13 
, with M = 3 cm-1, representative of Caucasian skin (31). The term μaunpigm, represents 
unpigmented tissue without blood or melanin and was assumed to be wavelength 
independent and equal to 0.3 cm-1 (31).  
The reduced scattering coefficient of skin was calculated with (31), ( )[ ] ( )[ ]λλλμ ⋅⋅+−⋅⋅+⋅= −− 514 1029620110551029 .B)(' skins    14 
Fig. 2 shows the modeled values for the absorption spectra of deoxy- and oxygenated blood 
(B=1%), the absorption of oxygenated Caucasian skin containing, and of the scattering 
coefficient of human skin. 
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Fig. 2 Modeled absorption coefficient: for deoxygenated (grey line) and oxygenated (solid line) blood, 
Caucasian oxygenated skin (dashed), and the reduced scattering coefficient of skin (grey dashed). The blood 
volume B = 1%. 
 
Variations in the standard input parameters 
The parameters were varied in the following ranges I: 30-100 mWcm-2, γ and η :0.3-1, 
Ca: 0.001-0.01 M. These were chosen rather arbitrarily, as literature values are not widely 
available. The fluorescence yields were assumed constant for each specific excitation-
emission wavelength pair. The scaling factors α, β and κ were also fixed, as these were based 
on a single measurements on a control tissue site. B was varied in the 0.1-10% range, (31, 34) 
StO2  was varied in the range of 10-100%, based on ref. (32) These ranges are representative 
of normal and tumor tissues. M was varied over 0.3-30 30 cm-1, encompassing the vales 
reported for Caucasian, Asian and African skin (31). The reduced scattering coefficient was 
varied by a factor of 10 above the standard values, based on reported values for normal and 
tumor tissues (35).  
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Table 2. Modeled fluorescence yields used in the different quantification methods.  
A: autofluorescence yield, H: marker fluorescence yield. 
Correction 
Method 
Excitation, emission 
wavelength pair [nm]
Fluorescence 
yield  
 [a.u] 
Uncorrected H 405,630 16 
 A 405,630 2 
Profio et al. A 410,562 4 
 H 410, 690 8 
Montan et al. A 337, 488 6 
 A 337, 600 1 
 H 337, 630 2 
Baumgartner et al. H 407, 630 16 
 H 470, 630 2 
 A 407, 630 2 
 A 470, 630 2 
Sinaasappel et al. A 405, 550 4 
 H 405, 630 16 
 H 435, 550 4 
 H 435, 630 2 
Saarnak et al. H410, 652 16 
 A410, 652 2 
 A 410, 510 4 
 
 
Results  
 
Quantification performance and signal change due to individual parameters   
The relative signal changes were plotted against variations in the input parameters, as 
shown in Fig. 3. The corresponding maximum signal changes are listed in Table 3. These 
results demonstrate that variations in I, η and γ could be entirely corrected (SC = 1.00) using 
the ratiometric methods of Profio et al. and Montan et al. However, these methods vary with 
the autofluorescence level and tissue optical properties. Converseley, variations in 
autofluorescence can be entirely corrected using the subtraction method of Baumgartner et 
al., but this varies with I, η and γ and the tissue optical properties. The method of 
Sinaasappel et al. entirely corrects for variations in I, η, γ and also substantially corrects for 
variations in tissue optical properties and auto-fluorescence. The method described by 
Saarnak et al. corrects for all parameters evaluated here. 
 
Total Signal Change 
 The total signal change, TSC,  is listed in Table 3 for the different methods.  In the 
ratiometric methods the largest contribution is due to a dependence on autofluorescence, 
followed by blood content.  In the subtraction method of Baumgartner et al. the largest 
contributions are from variations in tissue scattering, followed in decreasing order by I, η, γ, 
melanin content and blood content.  
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Fig. 3 Correction performance vs. (a) Irradiance, excitation geometry and collection efficiency, (b) 
autofluorescence, (c) blood volume, (d) blood oxygenation, (e) melanin content, and (f) tissue scattering. 
 
 
Discussion  
 
Model Calculations 
We here demonstrated that use of analytical solutions and models provide an 
understanding of the major parameters that contribute to the in vivo fluorescence signal andis 
a relatively simple and efficient approach to evaluate the quantification performance 
objectively.  
Due to the model assumptions, the results obtained here are valid if the fluorescent 
layer is exposed at the tissue surface and is optically thick relative to the penetration depth of 
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the excitation light. A guideline for this thickness may be found in studies of diffuse 
reflectance (here indicative of the excitation light), where the signal was found unchanged 
when the tissue was thicker than ~12 effective penetration depths (36). For UV excitation 
light, typical penetration depths of ~0.1-0.3 mm (35) have been reported for various 
biological tissues, in which case the fluorescent layer should be ~≥ 1-3 mm thick. Hence, 
this model has relevance in a large number of clinical applications where the lesions are 
exposed to the tissue surface and are up to several mm in depth, such as early lesion 
detection in dermatology and endoscopy, as well as image-guided surgical resection.   
A porphyrin was used as the model maker, however the results and conclusions 
obtained here will be generic to near-infrared fluorescent markers with respect to variations 
in irradiance, excitation-geometry, collection efficiency, and even autofluorescence, so long 
as the relative contribution to the raw uncorrected fluorescence signal falls within the ranges 
used here.  With respect to blood and melanin absorption, tissue- oxygenation and 
scattering, the performance can further improve when carefully selecting the marker and 
their excitation and emission wavelengths towards the near-infrared wavelength range (37), 
where tissue absorption and scattering decrease,  this is part of our ongoing research. 
 
Table 3. The Signal Changes and the Total Signal Change equal to product of the signal changes due to 
the individual parameters 
Signal Change  
due to variations in individual parameters  
Correction 
Method 
Total  
Signal 
Change I,γ,η Ca B StO2 M μ's
Uncorrected et al 1.72x103 3.33 1.11 1.82 1.01 3.50 6.51 
Profio (a) et al 1.18x101 1.00 9.00 1.17 1.02 1.01 1.10 
Baumgartner et al 1.55x103 3.33 1.00 1.82 1.01 3.50 6.51 
Montan et al 1.31x101 1.00 10.0 1.14 1.01 1.03 1.11 
Sinaasappel et al 1.42 1.00 1.16 1.03 1.03 1.10 1.05 
Saarnak et al 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
 
Signal changes due to individual parameters  
The results obtained here indicate that the subtraction method of Baumgartner et al. 
entirely corrected for variations in autofluorescence. The trade-off is a remaining 
dependence on variations in irradiance, excitation geometry, detection efficiency and tissue 
optical properties, since the subtraction does not cancel out any of these factors.  
The  methods of Profio et al., Montan et al.,  Sinaasappel et al. and Saarnak et al. make 
use of ratiometry and completely corrected for variations in irradiance, excitation geometry 
and detection efficiency, as these parameters cancel out in taking the ratio. This can be 
particularly useful in applications such as endoscopy, where these variations occur frequently 
and are note easily controlled. However, the trade-off for is a greater dependence on 
variations in the autofluorescence than even the uncorrected fluorescence signal itself, due to 
the large autofluorescence contribution in the denominator. The exception is the ratiometric 
method of Saarnak et al., which has the same contribution of autofluorescence in both 
numerator and denominator.  In these ratiometric methods the main reason for 
dependencies on tissue optical properties is the difference in optical properties between 
numerator and denominator. Correction for tissue optics is achieved in the method of 
Saarnak et al., through use of an image set without marker in the denominator. In the 
 79 
In vivo optical imaging of fluorescent markers for detection and guided resection of cancer 
Sinaasappel method it is largely achieved by using an image set at a different fluorescence 
yield in the denominator.  
 
Total quantification performance 
The total signal change listed in table 3 demonstrates that use of any of the methods 
gave improvement over the uncorrected signal. At fixed marker concentration, the 
uncorrected signal can change by a large factor (1.72x103) as a result of the variations in 
excitation irradiance, excitation geometry, collection efficiency, auto-fluorescence, blood 
volume, blood oxygenation, melanin content and tissue scattering.  
The method of Saarnak et al. demonstrated the best quantification performance, as it 
depends only on the concentration of the fluorescent maker. This method is based on image 
acquisition before and after marker administration and it requires these subsequent images to 
be taken on the same tissue site under identical geometry. Hence, the assumption is made 
that the optical properties and autofluorescence may change spatially within the image, but 
remain constant over the time interval between image acquisitions. This could be useful in 
any Application where these conditions could be met include lesion detection in 
dermatology and pre-clinical research where, before and after administration of the marker, 
the tissue of interest can be re-located and the geometry can be controlled, as is the case for 
the device reported by Xenogen Corp. (26).  
For many clinical applications, however, these conditions can not easily be met, e.g. 
in endoscopic screening, image-guided surgical resection or monitoring treatment response, 
as it may not be feasible to control the geometry and/or re-locate the tissue area of interest. 
The assumption that autofluorescence and tissue optical properties remain constant over the 
administration time of the marker may also not be valid since these can vary with treatment 
or surgery. In these cases the method of Sinaasappel et al., which does have such restrictive 
conditions could be used. This method demonstrated the best correction in cases where the 
geometry is not well controlled, correcting fully for variations in irradiance, excitation 
geometry and collection efficiency. Due to relatively small dependence on mainly 
autofluorescence the Total Signal Change was 1.42, which can be interpreted as an 
uncertainty of  ~ ± 20%. This should be acceptable in many applications.  In the other 
methods the Total Signal Change was more than a factor of 10,  which makes them 
unsuitable for any application where absolute or even relative quantification of the 
fluorescence signal is important.  
Kircher et a.l recently adapted the method of Profio et al. by replacing the 
autofluorescence with the fluorescence of a second marker (22, 23).  The variations in 
concentration of this second marker are not well established currently. However, if these are 
< ±5%, the TSC of this method would also be in the ~1.4 range, making it a suitable 
quantification method. 
Hence, use of these methods can substantially aid in vivo fluorescence quantification 
over use of the raw fluorescence signal.  As these can be computed and displayed in real-
time they are of particular interest for applications where direct feedback is critical as 
endoscopic screening and image-guided surgery.  
The use of existing-,  and the development of novel quantification methods based on 
continuous wave excitation and multi spectral image acquisition should therefore be further 
explored as these offer simple and efficient means for in vivo fluorescence quantification in 
real-time. 
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Abstract 
Future applications of ‘molecular diagnostic screening’ and ‘molecular image-guided 
surgery’ will demand images of molecular markers with high resolution and high throughput 
(~≥30 frames/sec). MRI, SPECT, PET, optical fluorescence tomography, hyper-spectral 
fluorescence imaging and bioluminescence imaging do not offer such high frame rates. 2D 
optical fluorescence imaging can provide surface images with high resolution and high 
throughput. The ability to accurately quantify the fluorescence in vivo is critical to extract 
functional information of the disease state, however few methods are available. 
 Here, a ratiometric 2D quantification method is introduced. Through mathematical 
modeling the performance was evaluated using optical properties that resembled biological 
tissues with the fluorescent marker Protoporhyrin IX. Experimentally the performance was 
evaluated in optical phantoms with different optical properties employing a prototype imaging 
system. The clinical feasibility of real-time, image-guided surgery was demonstrated in 
patients undergoing prostatectomy.  
Discussed are the reasons why the introduced method leads to an increased 
quantification performance followed by modifications so it can be applied to novel fluorescent 
molecular markers as phthalocyanine 4 and dual-fluorescent markers. These offer additional 
advantages as these can provide a linear response to marker concentration and further 
minimize the dependence on autofluorescence and optical properties, as demonstrated 
through modeling. 
 
 
Introduction 
 
Recent advances in genomics, proteomics and nanotechnology have enabled the engineering 
of nanoparticles that comprise a targeting moiety (such as antibodies, antibody fragments or 
peptides) conjugated to a marker ligant (1)  This marker can have ferromagnetic,  radioactive, 
echogenic, fluorescent or bioluminescent properties such that it can be visualized with the 
appropriate imaging device (magnetic resonance imaging (MRI), single-photon computed 
tomography (SPECT), positron emission tomography (PET), ultrasound or optical imaging, 
respectively) (2).   
Not only can imaging of these particles be used for early detection of cancer, 
excitingly, it can also yield functional information on a molecular level, about the 
invasiveness, progression and treatment response of the disease (3, 4). This information, 
directly available to the clinician during ‘molecular diagnostic screening’ or ‘molecular image-
guided surgery’, has the potential to improve clinical decision making and hence could 
ultimately improve diagnostic accuracy and outcome. To illustrate this, in breast cancer over 
expression of the human epidermal growth factor receptor 2 (HER-2) was shown to be 
associated with (a) the presence of disease, (b) involvement of  auxiliary lymph nodes (c) 
grade 3 tumors (d) resistance or benefit of specific adjuvant treatments and (e) poor 
prognosis (5). Hence, if it were possible to visualize and quantify HER-2 during surgical 
resection, this information may then be used (a) to enable more complete surgical resection, 
(b) as a decision criterion for lymph node resection, as direct assessment of (c) tumor grade 
and (d) for the rational selection of adjuvant treatments, to improve overall prognosis (e). 
Both applications of diagnostic screening and image-guided surgery demand high 
throughput, high resolution images of, in most cases, the tissue surface, with real-time 
display of ~≥ 30frames/sec. MRI, SPECT, PET, optical fluorescence tomography, hyper-
spectral fluorescence imaging and bioluminescence imaging do currently not offer such high 
frame rates due to the complexity of tomographic image acquisition and reconstruction (6), 
acquisition and unmixing of hyper-spectral data cubes (7, 8), or low bioluminescence photon 
budget (9). By contrast, 2D ultrasound and 2D optical fluorescence imaging do offer high 
 86 
In vivo optical imaging of fluorescent markers for detection and guided resection of cancer 
throughput imaging, whereas ultrasound typically offers B-scan images representing a section 
through the tissue and optical fluorescence imaging offers tissue surface images, at high 
resolution with relatively low technological complexity and significantly lower cost (3). 
Hence, the currently available imaging modality that could  meet the demands of 
‘molecular diagnostic screening’ and ‘molecular image-guided surgery’ is optical fluorescence 
imaging, since this can provide surface images at high throughput and high resolution and 
low cost.  
However, the ability to accurately quantify the in vivo fluorescence is critical to extract 
functional information of the disease state. (2). This, is a major challenge, because the in vivo 
fluorescence depends on many parameters other that the concentration of the fluorescent 
marker. Examples are variations in the tissue-to-detector geometry, autofluorescence and 
tissue optical properties, so that the raw fluorescence image can be subject to several artifacts 
that compromise accurate quantification (7, 9, 10 , 11).  
Several 2D fluorescence image quantification methods have been suggested in the 
literature that are based on multi-spectral image acquisition and subsequent image processing 
that employ subtractions and ratios. These are able to quantify fluorescence generated at the 
tissue surface. This is useful in endoscopic applications and, in most cases, for image-guided 
surgery, since various early tumors arise relatively superficially, in intra-epithelial layers at 
depths of a few hundred microns (12), while  tumor surfaces are exposed during surgical 
resection. We recently evaluated the quantification performance of these methods and 
demonstrated that it is possible to correct 2D images for large variations in geometry, 
autofluorescence and unknown tissue optical properties.  A method was identified that is 
well suited for applications as endoscopic screening or image-guided surgery. The variation 
in the output  signal of this method was < ± 20% as compared to orders of magnitude for 
the raw fluorescence, so that it can substantially aid in quantification (13).  
There are certain disadvantages to this method. The majority of this variation is 
caused by a remaining dependence on variations in autofluorecence.  Therefore, the 
detection systems requires a high sensitivity and dynamic range as it requires measurement of 
marker fluorescence and of only autofluorescence, which typically differ by an order of 
magnitude in signal strength. Further, it has a non-linear response to the marker 
concentration and reaches a plateau at higher concentrations.  
Therefore, it would be advantageous to develop novel quantification methods that 
are not dependent on variations in autofluorescence, do not require separate measurements 
of autofluorescence, and have a linear response to the concentration of the fluorescent 
marker over a wide range of concentrations.  Such methods should also be applicable to 
different fluorescent markers.   For experimental and clinical verification of these methods, 
prototype fluorescence imaging systems will need to be developed that can process and 
display the images in real-time, as these are currently non-existent.   
To address this need, here, a ratiometric quantification method is introduced. The  
performance was evaluated employing the mathematical model described previously (13). 
Optical properties used resembled biological tissues with the fluorescent marker 
Protoporhyrin IX (PpIX). We choose this marker as it is used clinically (14, 15) and will 
therefore likely form the baseline minimal signal strength that may be anticipated with novel 
molecular fluorescent markers. For experimental evaluation a prototype clinical fluorescence 
imaging system was developed that can process and display the images in real-time. Using 
this device the performance was evaluated in optical phantoms with different optical 
properties. The clinical feasibility of real-time, image-guided surgery was demonstrated in 
patients undergoing radical prostatectomy.  
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The reasons why this method leads to an increased quantification performance are 
discussed. Furhter, modifications of this method are presented so it can be used for NIR 
excitation and detection of phthalocyanine 4 (16), and,  applied to novel dual-fluorescent 
markers (17, 18).  These offer additional advantages as they can be conjugated to various 
targeting moieties, provide a linear response to marker concentration and further minimize 
the dependence on autofluorescence, as demonstrated through modeling. 
 
 
Materials and Methods 
 
Model Calculations 
In a similar fashion as described before (13), the correction performance was 
evaluated by describing the method analytically using mathematical descriptions for 
florescence emission from turbid media, defining standard input parameters and introducing 
variations around these standard values. For this, one parameter was varied at a time, with 
the other parameters fixed at their standard value. As a measure of the quantification or 
correction performance the factor, CP, was defined as the change in the corrected signal due 
to the introduced variations relative to the signal with the standard input parameters. The 
Signal Change index, SCparameter, was calculated as the maximum divided by the minimum 
correction performance and the total signal change, SCtotal, was defined as the product of the 
signal changes due to the individual parameters, at fixed target fluorophore concentration. 
An SCtotal of 1.50 can be interpreted as variation in output signal of  ≤ ± 25%. MATLAB® 
(The MathWorks Inc., US) was used for modeling and the code is available upon request. 
The fluorescence and diffuse reflectance were described as F(λex,λem) and R(λex) 
[mW.cm-2], where λex and λem stand for the excitation and emmission wavelengths [nm], 
respectively as summarized in Table 1.  
 
Table 1. Choosen excitation and emission wavelengths for methods and marker 
 
Method Marker λex1 λex2 λem1
   QRaw PpIX 406  630 
Q1 PpIX 406 436 630 
Q2 PC4 686 650 710 
Q3 Dual1 620  700 
Q3 Dual2 730  800 
Q4 Dual1 620 640 700 
Q4 Dual2 730 750 800 
 
The raw fluorescence signal, QRaw, uses a single excitation wavelength in the ultra 
violet (UV) to blue range  and a single emission wavelength in the far red to near-infrared 
(NIR) range and is described as,  ( 11 emexRaw ,FQ )λλ=         1 
 The ratiometric method introduced here, Q1, employs two excitation and two 
emission wavelengths. Using the first excitation wavelength at an absorption maximum of 
the fluorescent marker, the red marker fluorescence was divided by diffusely reflected 
excitation light. Subsequently, this fluorescence/reflectance ratio is divided by a 
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fluorescence/reflectance ratio excited at the second excitation wavelength at an absorption 
minimum of the marker, ( )
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Protoporhyrin IX (PpIX) was used as the model fluorescent marker and the 
excitation and emission spectra are shown schematically in Fig. 2. Both the PpIX 
fluorescence and the tissue autofluorescence, were based on previous measurements in 
human subjects (19).  
The fluorescence and diffuse reflectance emitted at the tissue surface was described 
by analytical solutions to the diffusion equation. These solutions were similar to those used 
in our previous study (13), differing only in that the formalisms used here are valid for 
excitation in the entire UV-NIR wavelength range. These formalisms have been validated 
and have demonstrated similar accuracy  as compared to Monte Carlo modeling (20),   ( ) [ ]
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The dimensionless functions, γ and η include the influence of geometry on the 
excitation irradiance and the collection efficiency of the photo detector, respectively.  Cm and 
Ca  stand for the fluorescent marker and auto fluorophores concentrations [M], with 
fluorescence yields, M(λex,λem) and A(λex,λem) [cm-1.M-1], respectively. The excitation 
irradiance is given by I(λex) [mW.m-2]. D(λ) is the optical diffusion coefficient, 
, where μ’( ) ( )[ 13 −= λμλ t'D ] t(λ) [cm-1] is given by ( ) ( ) λμλμλμ totalast '' += ( ) , μ’s(λ)  is the 
reduced scattering coeficient and μatotal(λ) is the absorption coefficient of the tissue 
fluorophores (target plus auto), so that ( ) ( ) (λμλμλμ esfluorophoratissueatotala += ) . The 
effective attenuation coefficient μeff(λ) is given by, ( ) ( ) ( ) ( )[ ]λμλμλμλμ stotalatotalaeff '+= 3 . The 
absorption of the tissue was considered much larger than that of the fluorescent marker plus 
auto fluorophores,  (μatissue>>μamarker + autofluor), so that μamarker + autofluor was negligible in calculating 
D(λ),  μ’t(λ) and μeff(λ).  
 
The standard values for optical properties of biological tissues were determined using 
the model by Svaasand et al. (21). According to this the parameters that dominate absorption 
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of human skin in the visible to near-infrared wavelength range are blood volume, blood 
oxygenation and melanin content.  
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Fig. 1 Modeled absorption coefficient: for deoxygenated (grey line) and 90% oxygenated (solid line) blood, 
tissue (dashed), and the reduced scattering coefficient of tissue (grey dashed). The blood volume B = 2%. 
 
Since most tissues but skin do not contain melanin we here modified this model by 
decreasing the melanin content by a factor of 3 from that of Caucasian skin (@694nm), so 
that it here represents unknown absorbers. Hence, this modified model produces optical 
properties that are generally more representative of tissues that do not contain melanin (22) 
and at 630 nm were in the range of brain white matter (23). Fig. 1 shows the modeled values 
for the absorption of deoxy- and 90% oxygenated blood (standard), the tissue absorption 
with oxygenated blood, and the tissue scattering coefficient.  
 
Table 2. Modeled fluorescence yields used in the different quantification methods.  
 M: marker fluorescence yield, A: autofluorescence yield 
 
Marker λex, λem  
[nm] 
M 
[a.u]
A 
[a.u] 
PpIX 406, 630 16 2 
 436, 630 4 1.8 
PC4 656, 710 4 0.2 
 686, 710 16 0.18
DF 620, 700 16 0.22
 640,700 4 0.20
 730, 800 16 0.15
 750, 800 4 0.13
 
The standard values for fluorescence yields M(λex,λem) and  A(λex,λem) are listed in Table 
2. These were assumed constant. Their relative magnitudes were estimated based on the 
excitation and emission spectra shown in Fig. 2. The standard values for the remaining 
parameters and the range over which they were varied are listed in Table 3. Listed values for 
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I, γ, η and Ca were chosen rather arbitrarily, as literature values are not widely available,  
however ranges for B, StO2 and  μ’s span reported values for normal and cancerous tissues. 
 
Table 3. Parameter standard values and the ranges over which they were varied 
 
Parameter Standard Range Unit Ref. 
I 100 30-100 mWcm-2 (13) 
γ, η 1.0 0.3-1.0 r.u (13) 
Cm 0.01 fixed M - 
Ca 0.01 0.002-0.02 M (13) 
B 2 1-10 % (27) 
StO2 90 30-90 % (27) 
μ’s 1.0 0.1-1.0 r.u. (22) 
 
Optical Phantoms 
Experimental performance evaluation was conducted in tissue equivalent phantoms 
with Intralipid-20% as scattering media and Evans Blue as absorber. These were prepared 
with 3 different sets of μa  and μ's at 630nm. Values are listed in Table 4 and fall within ranges 
used above for modeling. In these experiments I, γ and η were kept constant. PpIX (Sigma-
Aldrich, Canada) was used as target fluorophore. Because of the hydrophobic nature of 
PpIX, prior to use the phantoms were shaken continuously for 72h to allow PpIX to bind to 
the lipids. The raw fluorescence and the signal output of Q1 were determined over a PpIX 
concentration range of 0.01-10μg/ml. Also, the lower detection limit of PpIX was 
investigated. 
Table 4. Phantom optical properties at 630 nm. 
 
Phantom μ's  μa  
[cm-1][cm-1]
1 15 0.25 
2 30 0.5 
3 60 1 
 
Optical imaging was performed with a newly developed prototype fluorescence 
imaging system that was designed for clinical use. This is based around a 3-CCD compact 
surgical camera (DXC-C33, Sony, Canada). Multi-spectral images are acquired using the blue, 
green and red channels. The sensitivity towards the NIR can be extended by replacing the 
standard NIR cut-off filter. This camera features a frame rate of 30 frames/sec (NTSC), 796 
x 494 pixels and 8 bit dynamic range. A standard clinical laparoscope with a liquid light guide 
coupled to the excitation light source is serving as excitation and entrance optics. A custom-
made long-pass 500nm filter is placed between the camera and laparoscope. This purposely 
leaks a small fraction (10-4) of the UV/blue excitation light (Chroma, US) for measurement 
of the diffuse reflectance. The custom-made excitation light source is a 300W Xeon arc lamp 
(Cermax, Perkin Elmer, US).  A filter wheel containing 2 excitation filters (wavelengths listed 
in Table 1) spins at a frequency so that subsequent frames are excited with alternating 
wavelengths. The excitation irradiance with the filters is ~50 mW.cm-2, at a typical working 
distance of 2 cm.  The digital video output is captured by a computer (Intel, Pentium 4) and 
can be displayed on the monitors in the operating room for visualization to the surgeon, 
hence allowing surgical guidance. Image processing is performed with custom made software 
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(Hytek Automation, Waterloo, ON, Canada) that is based on LabVIEW™ (National 
Instruments, US).  
A general problem with correction methods is that the structural/anatomical 
information is mostly lost. This is problematic when the images are used to guide biopsies or 
resect tumors. To alleviate this problem, the software allows to superimpose/overlay the 
corrected image on the raw fluorescence images in real-time, providing both structural 
information for orientation and functional information.  
 
Clinical feasibility 
Quantitative fluorescence imaging employing Q1 was performed in patients with 
prostate cancer undergoing radical prostatectomy. Approval for this study was obtained 
from the research ethics board of the University Health Network and patients agreed to 
participation by signing a consent form. This study is ongoing and to date 6 patients have 
been enrolled, hence the results obtained here are preliminary in nature and serve the 
purpose only of demonstrating clinical feasibility. To induce PpIX, 20 mg/kg 5-
aminolevulinic acid (ALA) was administered orally in 50ml of orange juice 5-6 h prior to 
fluorescence imaging. We investigated feasibility of using Q1 in real time for image-guided 
surgery using the above described prototype imaging device.  
 
 
Results 
 
Model caclulations 
The signal change due variations in one parameter, SCparameter, and the total signal change,  
SCtotal , due to variations in all parameters are listed in Table 5.  
 
Table 5. The signal change due to variations in the individual parameters, SCparameter , and the total signal 
change, SCtotal, for each method and each marker. γ: excitation geometry, η: collection efficiency, I: Irradiance, 
Ca: Autofluorescence, B: Blood volume, StO2: Oxygenation, μs’: Scattering,  
(Indep.: Independent by definition). 
 
Method Marker Linear SCI,γ,η SCCa SCB SCStO2 SCμs SCtotal
   QRaw PpIX ; 3.33 1.22 4.47 1.07 1.14 245 
Q1 PpIX  : Indep. 1.23 1.03 1.17 1.07 1.59 
Q2 PpIX  : Indep. 1.24 1.21 1.77 1.12 2.97 
Q1 PC4  : Indep. 1.08 1.01 1.01 1.02 1.12 
Q3 Dual ; Indep. 1.07 1.05 1.05 1.04 1.23 
Q4 Dual Indep. Indep. 1.02 1.05 1.04 ; 1.11 
 
Optical phantoms 
In the tissue phantoms increasing signal was observed with increasing PpIX 
concentration for both the raw fluorescence and method Q1 as shown in Fig. 3. The raw 
fluorescence signals in Fig. 3a demonstrate a large deviation in response between the 3 
phantoms. At a PpIX concentration of 1.25μg/mg the maximum difference between 
phantom 1 and 3 is ~200%, confirming the need for correction methods. Fig. 3b shows the 
signal according to Q1 with obvious decreased deviation between the response curves. At 
1.25μg/mg the maximum difference has decreased 10-fold to ~20%. At lower PpIX 
concentrations a plateau was reached that we interpreted as the lower detection limit as 
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indicated by the dashed lines in Fig. 3a. This plateau was not determined by camera noise, 
but by the autofluorescence of the phantom, as confirmed by switching off the excitation 
light.  
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Fig 3. (a). raw fluorescence intensity vs. PpIX concentration for the 3 phantoms listed in Table 1. These 
have a large variation in response due to the different optical properties of these phantoms. The difference 
between phantom 1 and 3 at 1.25μg/ml PpIX is ~200%. The lower detection limit of PpIX is indicated 
by the dashed lines. (b) The same data set as shown in (a) but now corrected according to Q1, note that the 
deviation between the response curves has decreased in (b) vs. (a) as the 3 separate curves of (a) have collapsed 
to one universal response curve, the difference between phantom 1 and 3 at 1.25μg/ml PpIX has decreased 
by a factor of 10 to  ~20%. 
 
 
Clinical Feasibility 
Intraoperatively, the capsule of the prostate also showed a green autofluorescence 
with small amounts of diffusely reflected UV/blue excitation light. Various areas with red 
fluorescence were found on the prostate capsule and surgical bed. A typical example is 
shown in Fig. 4. The device was able to compute, display and store method Q1 in real time 
(30 frames/sec) without dropping frames.  
 
a b c d e
Fig. 4 (a) A white light image of the prostate capsule with forceps around a nodule. (b) The raw unprocessed 
raw fluorescence image showing small amounts of blue reflectance, green autofluorescence of the prostate capsule 
and bright red fluorescence of the nodule. (c) The same fluorescence image now made quantitative through 
image processing according to method Q1. As can be observed most of the anatomical/structural information 
is lost. To alleviate this problem this image is thresholded (blue = 0 intensity) as shown in (d) and overlaid 
on the raw fluorescence image so that the resulting (e) image contains both structural/anatomical information 
as well as functional quantitative information.  
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Discussion 
 
Model Calculations 
Method Q1 demonstrated a quantification performance of SCtotal  = 1.59, which can 
be interpreted as a variation in the output signal of ~ < ± 30%.  This is an improvement of 
more than 2 orders of magnitude as compared to the raw fluorescence (SDtotal = 245) and in 
a similar performance range compared to the method by Sinaasappel et al. (SDtotal =1.42) (13). 
The advantage of Q1 over this method is that less sensitive detectors with a lower dynamic 
range can be employed as it measures diffuse reflectance instead of autofluorescence.  
The key to the high performance of Q1 is the ratio that cancels out variations in 
irradiance, excitation geometry and collection efficiency. A small fraction of 
autofluorescence plus large fraction of marker fluorescence present in both numerator and 
denominator minimizes the dependence on variations in autofluorescence. Correction for 
optical properties is achieved by representing these equally in the numerator and 
denominator by combining fluorescence and reflectance. To demonstrate the effect of the 
reflectance term in Q1 we also modeled the performance without it. We referred to this as Q2 
and the results are listed in Table 5. Q2 had a decreased performance (SCtotal  = 2.97)  as 
compared to Q1 (SCtotal  = 1.59) demonstrating that use of the reflectance term minimizes the 
dependency on optical properties.  
 
Optical phantoms 
The quantification performance of Q1 was evaluated experimentally in tissue 
equivalent phantoms employing a prototype fluorescence imaging system that was able 
compute, display and store Q1 in real-time. The results demonstrated that the response curve 
of the raw fluorescence vs. marker concentration was different for each of 3 phantoms 
confirming the need to correct for variations in optical properties. Employing Q1 minimized 
this difference in the response by 10-fold, resulting in a more universal response curve 
demonstrating the ability of this method to correct for variations in tissue optical properties. 
 
Clinical feasibility  
We investigated the clinical feasibility of using Q1 and the here developed prototype for 
image-guided surgery. Intraoperatively, six patients with prostate cancer undergoing radical 
prostatectomy were examined after ALA-induced PpIX administration with the purpose to 
detect fluorescence on the prostate capsule. Pathology and PpIX extraction data are not 
available at present as this trial is currently ongoing.  However, the preliminary clinical results 
obtained here demonstrated that the device was capable of detecting diffuse reflectance, 
auto- as well as marker (PpIX) fluorescence, and can compute and display Q1 in real-time 
(30frames/sec). As an additional feature the correction method can be overlayed on the raw 
uncorrected fluorescence image, in real time, essentially combining the structural anatomical 
information with the functional quantitative information.  
 
Modifications  
We choose PpIX as marker because it is currently in clinical use (14). Recently reported 
results of a Phase III trial in 270 patients demonstrated that fluorescence image guided 
resection of malignant gliomas doubled the 6 month progression free survival over resection 
under white light (15). Hence, PpIX fluorescence will likely form the baseline minimal signal 
strength that may be anticipated with novel molecular fluorescent markers. 
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 Method Q1 is modified below so it can be applied to such novel markers and the 
performance is evaluated through modeling as above. 
The excitation and emission wavelengths used are listed in Table 1. Fluorescence 
yields are listed in Table 2 and were estimated from marker absorption and emission spectra 
available in the literature (16-18) and schematically shown in Fig. 2.  
Method Q1 can be used with markers that absorb and emit in the NIR range as 
phthalocyanine 4 (PC4) (16). Due to the 
decreased autofluorescence, blood 
absorption and scattering in the NIR the 
performance, further improved to SCtotal  
= 1.12, as listed in Table 5. 
As method Q1 is based on a ratio 
on the maxima and minima of the 
absorption spectra, the response to the 
marker concentration is non-linear and 
reaches a plateau at higher 
concentrations, similar to the method by 
Sinaasappel et al. (24). Therefore, the 
concentration range that can be 
determined is limited and hence it would 
be beneficial to modify Q1 such that it 
would have linear response to marker 
concentration. This can be achieved by 
using Q1 in combination with recently 
reported dual fluorescent markers (17, 
18). These are two markers with different 
absorption and emission spectra 
conjugated to a single targeting moiety, 
as shown in Fig 2. The fluorescence of 
one marker can vary to yield functional 
disease information, whereas the 
fluorescence of a second marker is used 
as reference and assumed constant. 
Placing their signal in the numerator and 
denominator of Q1 respectively is 
referred to as Q3, the performance is 
SCtotal  = 1.23 as listed in Table 5 is in a 
similar range as compared to Q1 with 
PC4, but has the additional advantage of 
a linear response to marker 
concentration.  
Q3 is dependent on variations in 
autofluorescence. This can be subtracted 
using the subtraction method of 
Baumgartner et al. (13, 25) (now widely 
used by Xenogen Corp. (26)), in both 
numerator and denominator, so that the 
method  Q4 is independent on variations 
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a
b
c
Fig. 2 Schematic excitation (grey line) and emission 
(black line) spectra of tissues containing the marker (a) 
Protoporhyrin IX (PpIX), (b) Phthalocyanine 4 (PC4) 
and (c) a Dual fluorescent marker (DM). The dashed line 
shows the tissue auto fluorescence. 
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in auofluorescence and the performance further improves to SCtotal  = 1.11. Details regarding 
modeling for this method can be found in ref. (13). 
Note that, for fluorescence quantification with optimum accuracy, the fluorescent 
layer should be exposed to the tissue surface and should be thick relative to the penetration 
depth of light (13). Hence, UV/blue excitation light should be used for quantification of 
fluorescence in small lesions of a few mm in depth whereas far red/NIR light excitation can 
be used for thicker lesions. This because the effective penetration depth of UV vs. NIR light 
changes form the sub-millimeter range to several millimeters (22).  
 
 
Conclusions 
 
The modeling and optical phantom experiments demonstrated that the method 
introduced here substantially aids in the in vivo quantification performance over use of raw 
fluorescence signal. Due to its relative simplicity we also demonstrated it can be acquired, 
computed and displayed in real-time (30 frames/sec). The clinical feasibility of this was 
shown by using this method intra-operatively during radical prostatectomy of patients with 
prostate caner.  
Several modifications of this method are discussed so it can be used with NIR 
markers as phthalocyanine 4 (16) or with dual-fluorescent markers (17, 18).  These offer 
additional advantages as they can be conjugated to various targeting moieties, provide a 
linear response to marker concentration and further minimize the dependence on 
autofluorescence, as demonstrated through modeling. 
These methods could be of value for future clinical applications of molecular 
imaging, in particular diagnostic screening and image-guided surgery where real-time 
feedback and accurate quantification will be required to reveal functional disease 
information.    
Hence, initial steps towards establishing the core methods and imaging technology 
needed for clinical in vivo real-time molecular imaging are presented. Major challenges remain 
in that future work should be directed towards experimental and clinical validation of this 
method for specific applications.       
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Summary  
 
Fluorescent molecules, hereafter referred to as fluorophores, can be excited by 
illumination with light and subsequently can  de-excite into the ground state through, 
amongst others possibilities, emission of fluorescence. In case the fluorophore is selectively 
taken up by the cancer and not by surrounding normal tissues the fluorescence may thus be 
used for the detection and localization of cancers.  
 
The research described in this thesis focuses on the development of methods and 
technology for real-time in vivo fluorescence imaging for cancer detection and image-guided 
surgical tumor resection. Subsequently, the introduced methods and technology are 
evaluated through modelling studies and validated with pre-clinical experiments and clinical 
trials in patients.       
 
After a general introduction in Chapter 1, Chapter 2 describes the development of a 
fluorescence imaging device for the detection of superficial cancer based on the Double 
Ratio technique. In practical use this device resembles an operation microscope and can be 
used in a clinical environment. This device acquires 4 different fluorescence images excited 
at two wavelengths each detected at two wavelengths. From these images it calculates, 
displays and stores Double Ratio images at a maximum speed of 1Hz. The Double Ratio 
image gives the distribution of the fluorophore amount present in tissue and is not affected 
by local variations in tissue optics, i.e. tissue absorption and tissue scattering. The validity of 
the technique was confirmed here by ex vivo tissue equivalent phantom experiments using 
hematoporphyrin and in vivo experiments on normal pigmented moles on Caucasian human 
skin using aminolevulinic acid (ALA) induced protoporhyrin IX (PpIX) as the fluorophore 
of interest.  
 
In Chapter 3 we investigated if the device described in Chapter 2 could be used as an 
imaging technique for the diagnoses of cervical intraepithelial neoplasia (CIN) in patients. 
For this purpose we performed a clinical trial, enrolling 38 patients. PpIX was induced by 
topical application of ALA, 16 of 38 patients were colposcopically selected for biopsy. Of 
these 16 patients fluorescence images were taken and 19 sites were biopsied and the disease 
was staged histopathologically. Fluorescence imaging of the cervix was cumbersome but 
feasible. In 4 cases strongly localized fluorescent hotspots were observed at the location 
where the disease was colposcopically visible. In the other cases the fluorescence showed a 
more diffuse multi-focal image. The value of the DR determined at the site of biopsy 
correlated in a statistically significant way with the histopathologically determined stage of 
the disease (Spearman rank correlation, r = 0.881, p<0.001 (confidence interval 0.7044 - 
0.9552)). The results indicate that not only detection of CIN was possible but, interestingly, 
also suggests that non-invasive staging of CIN using this technique appears feasible. 
  
The hypothesis of the study described in Chapter 4 is that fluorescence image-guided brain 
tumor resection can assist neurosurgeons by visualizing tumor margins that merge 
imperceptibly into normal brain tissue and, hence, are difficult to identify. To test this 
hypothesis we performed a pre-clinical study in which we compared residual tumor, 
determined by histopathology, after white light resection (WLR) using an operating 
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microscope versus additional fluorescence guided resection (FGR). For this, we used a rabbit 
model with intracranial VX2 tumor. Using a fluorescence imaging system we detected the 
fluorescence of ALA induced PpIX at 4 h before surgery.  The results demonstrated that 
using FGR in addition to WLR significantly decreased the amount of residual tumor post 
resection by a factor 16 from 32% ± 38% to 2.0% ± 3.5% of the initial tumor volume. 
Based on these results we concluded that adjuvant FGR significantly decreases residual 
tumor and enabled consistent resection completeness for all cases. 
 
Fluorescence-guided resection (FGR) and photodynamic therapy (PDT) have 
previously been investigated separately with the objectives, respectively, of increasing the 
extent of tumour resection and of selectively destroying residual tumour post resection. Both 
techniques have demonstrated trends towards improved survival, pre-clinically and clinically. 
In Chapter 5 we hypothesize that combining these techniques will further delay tumour re-
growth. In order to demonstrate technical feasibility of this approach, we used the same 
model as described under chapter 4, the rabbit with intracranial VX2 tumor. An operating 
microscope was used for white light imaging and the fluorescence imaging device described 
in Chapter 4 was used for FGR.  PDT treatment light was applied by intracranially-
implanted light emitting diodes (LED). The fluorescent photosensitizer used for both FGR 
and PDT was ALA-induced PpIX. For PDT, ALA (100mg/kg) and low light doses (15 and 
30J) were administered over extended periods, which we refer to as metronomic PDT 
(mPDT).    
18 tumour bearing rabbits were divided equally into 3 groups: controls (no 
resection); FGR; and FGR followed by mPDT. Histological whole brain sections (H&E 
stain) showed primary and recurrent tumours. No bacteriological infections were found by 
Gram staining. Selective tumour cell death through mPDT-induced apoptosis was 
demonstrated by TUNEL stain. These results demonstrate that the combined treatment is 
technically feasible and this model is a candidate to evaluate it. Further optimization of 
mPDT treatment parameters (drug/light dose rates) is required to improve survival.  
 
More recent research is shifting the focus towards novel fluorescent markers that use 
active targeting strategies. Recent advances in nanotechnology and increasing knowledge of 
genes and proteins associated with cancers has enabled the engineering of nanoparticles that 
comprise a targeting moiety (e.g. antibodies, antibody fragments, peptides) conjugated to a 
fluorescent marker. These particles hold promise to have an increased, more stable spectral 
intensity and improved tumor specificity compared with passive-targeting fluorescent 
markers. In addition to providing information about the presence or absence of disease, as 
was typically the case for passive-targeting markers, active-targeting markers can also yield 
functional disease information about physiological and molecular processes that relate to the 
invasiveness, progression and treatment response of the disease  
The ability to accurately quantify the in vivo measured marker fluorescence is critical 
to unravel functional disease information. However, qantification of optically measured 
fluorescence signals is a major challenge because the measured signals are strongly 
influenced by various secondary parameters. Over the last 2 decades several methods have 
been reported for quantification of passive-targeting fluorescent markers. These methods 
may be applied to imaging of novel, more tumor specific, active-targeting fluorescent 
markers. However, an objective comparison of these methods has not been reported.  
Therefore, in Chapter 6, we evaluate the performance of quantification methods for 
surface imaging that use continuous wave excitation (since these can be computed in real-
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time and thus be used for diagnostic screeining and image guided surgery). Each method was 
described by an analytical solution to the diffusion equation and the input parameters, 
irradiance, excitation geometry, collection efficiency, autofluorescence, melanin content, 
blood content, blood oxygenation and tissue scattering were varied over a range that can be 
expected during in vivo imaging, using optical properties resembling human skin containing a 
porphyrin-like target fluorophore.  
The uncorrected fluorescence signal changed by more than 3 orders of magnitude. 
The method of Saarnak et al. did not change and hence corrects entirely, but requires a 
constant geometry before and after administration of the fluorescent molecule. The method 
of Sinaasappel et al. resulted in a maximum uncertainty of ±20% in the fluorescence signal. 
Hence, these methods can aid in more accurate real-time quantification of active-targeting 
fluorescent markers. 
 
As described in Chapter 6 a major challenge is accurate quantification of the in vivo 
fluorescence signal in real-time. To address this problem, in Chapter 7, a ratiometric 
quantification method is introduced. Through mathematical modeling the performance was 
evaluated using optical properties that resembled biological tissues with the fluorescent 
marker Protoporhyrin IX. Experimentally the performance was evaluated in optical 
phantoms with different optical properties employing a prototype fluorescence imaging 
system. The clinical feasibility of real-time, image-guided surgery was demonstrated in 
patients undergoing prostatectomy.  
The modeling and optical phantom experiments demonstrated that this method 
substantially aids in the in vivo quantification performance over the use of existing ratiometric 
methods. We also demonstrated that this method can be acquired, computed and displayed 
in real-time (30 frames/sec) in patients undergoing radical prostatectomy. 
Discussed are the reasons why the introduced method leads to an increased 
quantification performance followed by modifications so it can be applied to novel 
fluorescent molecular markers as phthalocyanine 4 and dual-fluorescent markers. These 
offer additional advantages as these can provide a linear response to marker concentration 
and further minimize the dependence on autofluorescence and optical properties, as 
demonstrated through modeling. 
 
Hence, we made initial steps towards establishing the core methods and imaging 
technology needed for clinical in vivo real-time fluorescence molecular imaging. Major 
challenges remain in that future work should be directed towards experimental and clinical 
validation of these methods for specific clinical applications.       
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Samenvatting  
 
Fluorescerende moleculen, hierna fluoroforen genoemd, kunnen door bestraling met 
licht in een geëxciteerde toestand gebacht worden, waarna ze terug kunnen vallen in de 
grondtoestand via onder andere emissie van fluorescentie. Indien de fluorofoor selectief 
opgenomen wordt door kankercellen, en niet door omliggend nomaal weefsel, zou detectie 
van de fluorescentie dus gebruikt kunnen worden voor kankerdetectie.  
 
Dit proefschrift richt zich op de ontwikkeling van momenteel niet aanwezige 
methodes en technieken voor in vivo kwantitatieve beeldvorming van de fluorescentie voor 
kankerdetectie en resectie van tumoren. De geïntroduceerde methodes en technieken 
worden vervolgens geëvalueerd met modelstudies en gevalideerd met pre-klinische 
experimenten en met klinisch onderzoek in patiënten.  
  
Na een algemene introductie in Hoofdstuk 1 beschrijft Hoofdstuk 2 de ontwikkeling 
van een fluorescentiebeeldvormingssysteem voor de detectie van oppervlakkige tumoren 
gebaseerd op de Dubbele Ratio-methode. In de praktijk lijkt dit systeem op een 
operatiemicroscoop en kan gebruikt worden in een klinische omgeving. Het systeem 
detecteert vier verschillende fluorescentiebeelden, geëxciteerd en gedetecteerd met twee 
verschillende golflengtes licht. Gebaseerd op deze beelden wordt het Dubbele Ratio-beeld 
berekend en weergegeven, met een maximum beeldfrequentie van 1 Hz. Het Dubbele Ratio-
beeld geeft de distributie van de fluorofoor in weefsel weer en is onafhankelijk van lokale 
variaties in de weefseloptica, d.w.z. weefselabsorptie en -verstrooiing. De geldigheid van de 
methode was eerder bevestigd door i) ex vivo experimenten in weefselsimulerende fantomen, 
gebruik makend van de fluorescentiemarker hematoporphyrine-derivaat, en ii) door in vivo 
experimenten in mensen met gepigmenteerde moedervlekken op een lichte huid. Daarbij 
werd de marker protoporphyrine IX (PpIX) gebruikt, die werd aangemaakt door topicale 
toediening, oftewel via de huid, van aminolevulinezuur (ALA) .    
  
In Hoofdstuk 3 onderzoeken we of het systeem beschreven in Hoofdstuk 2 
gebruikt zou kunnen worden voor de diagnose van cervicale intraepitheliale neoplasia (CIN), 
oftewel voorstadia van baarmoederhalskanker, in patiënten. Hiervoor is een klinische 
onderzoek uitgevoerd in 38 patiënten. PpIX werd ingebracht door topicale toediening van 
ALA. Met behulp van een colposcopie (kijkonderzoek) werden 16 van de 38 patiënten 
geselecteerd voor biopsie. Uit die 16 patiënten werden 19 biopten (stukjes weefsel) genomen, 
waarvan werd bepaald in welk stadium van kwaadaardigheid (maligniteit) ze verkeerden door 
middel van microscopisch onderzoek (histopathologie). Fluorescentiebeeldvorming was niet 
eenvoudig maar wel haalbaar. In vier patiënten observeerden we sterk gelokaliseerde 
fluorescentie op een locatie waar de maligniteit zichtbaar was met colposcopie. In de andere 
gevallen gaf het fluorescentiebeeld een meer diffuus en multifocaal beeld weer. De grootte 
van het Dubbele Ratio-signaal zoals bepaald op de locatie van het biopt correleerde met de 
graad van de maligniteit zoals bepaald door histopathologie. Deze correlatie was significant 
(Spearman rank correlatie, r = 0.881, p<0.001 (zekerheidsinterval 0.7044-0.9552)). Deze 
resultaten demonstreren dat niet alleen detectie van een kwaadaardige afwijking mogelijk is 
met deze methode, maar dat ook het graderen van de maligniteit haalbaar lijkt. 
 
 103 
In vivo optical imaging of fluorescent markers for detection and guided resection of cancer 
De hypothese van het werk beschreven in Hoofdstuk 4 is dat 
fluorescentiebeeldvorming de neurochirurg tijdens tumorresectie kan helpen bij het 
visualiseren van tumorgrenzen. De tumoren dringen namelijk onzichtbaar door in het 
normale hersenweefsel, waardoor ze moeilijk te identificeren zijn. De hypothese is getest 
door het uitvoeren van een pre-klinische studie. Daarbij bepaalden we met histopathologie 
het tumorresidu na resectie onder wit licht met een operatiemicroscoop en vergeleken dat 
met het tumorresidu na witlichtresectie gevolgd door fluorescentie-geassisteerde 
tumorresectie (FGR). Hiervoor gebruikten we een konijnmodel met intracraniale VX2-
tumor. Met een fluorescentiebeeldvormingssysteem exciteerden en detecteerden we de 
fluorescentie van PpIX, die aangemaakt was na toediening van ALA vier uur voor de 
tumorresectie. De resultaten laten zien dat, gebruik makend van FGR na de witlichtresectie, 
het tumorresidu dat achterblijft na resectie significant afneemt met een factor 16, namelijk 
van 32% ± 38% naar 2.0% ± 3.5% van het initiële tumorvolume. Gebaseerd op deze 
resultaten concluderen wij dat FGR leidt tot een significante afname van het tumorresidu.  
 
Fluorescentie-geassisteerde resectie (FGR) en fotodynamische therapie (PDT) zijn eerder 
apart onderzocht met als doel respectievelijk een kleiner tumorresidu en het selectief 
vernietigen van tumorresidu. De pre-klinische en klinische resultaten van beide technieken 
hebben, apart van elkaar, trends laten zien die wijzen op een verbeterde prognose. In 
Hoofdstuk 5 introduceren we de hypothese dat het combineren van deze technieken leidt 
tot het verder vertragen van teruggroei van de tumor. Om de haalbaarheid van deze 
combinatie aan te tonen, maakten wij gebruik van hetzelfde model als beschreven in 
Hoofdstuk 4, namelijk het konijnmodel met intracraniale VX2-tumor. Een 
operatiemicroscoop werd gebruikt voor resectie onder wit licht en hetzelfde systeem als 
beschreven onder Hoofdstuk 4 werd gebruikt voor FGR. De lichtdosis benodigd voor PDT 
werd toegediend met behulp van lichtgevende diodes (LEDs). De lichtgevoelige stof 
gebruikt voor FGR en PDT was PpIX, geïnduceerd door ALA. Voor PDT werden ALA 
(100 mg/kg) en lage lichtdoses (15 en 30 J) toegediend gedurdende lange periodes. We 
refereren hiernaar als metronomische PDT (mPDT). Achttien tumordragende dieren werden 
gelijkelijk verdeeld over drie groepen: een controlegroep (geen resectie), FGR, en FGR 
gevolgd door mPDT.  
Histologie van complete secties van het brein (H&E) toonden primaire en 
teruggroeiende tumoren aan. Met Gram-kleuring werden geen bacteriologische infecties 
aangetoond. Selectieve dood van tumorcellen werd gedemonstreed met behulp van 
confocale microscopie en TUNEL-kleuring. Deze resultaten tonen aan dat de 
gecombineerde behandeling technish haalbaar is en dat dit diermodel een kandidaat is voor 
evaluatie van de combinatiebehandeling. Verdere optimalisatie van de mPDT 
behandelingsparameters is nodig om de prognose te verbeteren.   
 
Meer recent onderzoek richt zich op nieuwe fluorescentiemarkers die gebruik maken 
van actief-doelzoekende strategieën. Recente vooruitgang in de nanotechnologie en een 
toenemende kennis van genen en eiwitten die geassocieerd worden met kanker hebben er 
toe geleid dat nanodeeltjes gemaakt kunnen worden die bestaan uit een doelzoekend deel 
(bijv. antilichamen, antilichaamfragmenten, peptides) gebonden aan een fluorescerende 
marker. Deze deeltjes beloven een toegenomen, meer stabiele spectrale intensiteit en 
verbeterde tumorselectiviteit vergeleken met passief-doelzoekende markers. 
Behalve informatie over de aanwezigheid van kanker, zoals meestal het geval voor 
passief-doelgerichte markers, kunnen actief-doelgerichte markers ook infomatie op 
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functioneel moleculair niveau geven over de gradering van de ziekte, ziektemechanismen, de 
prognose van de patiënt en de behandelingsrespons. Om dit soort functionele informatie te 
kunnen achterhalen is het quantificeren van het in vivo fluorescentiesignaal essentieel. 
Accurate kwantificatie van in vivo gemetenfluorescentie vormt echter een uitdaging, omdat 
het gemeten signaal sterk afhangt van diverse secundaire parameters. In de laatste 20 jaar zijn 
verschillende correctiemethodes gerapporteerd voor de beeldvorming van passief-gerichte 
fluoroforen. Deze methodes kunnen wellicht ook gebruikt worden voor het kwantificeren 
van actief-gerichte fluoroforen. Een objectieve vergelijking van deze methodes is echter nog 
niet gerapporteerd. 
Daarom evalueren we in Hoofdstuk 6 de kwantificeringsprestaties van methodes die 
geschikt zijn voor oppervlakkige beeldvorming en die gebruik maken van continue excitatie. 
We beschreven elke methode met een analytische oplossing van de diffusietheorie. De 
invoerparameters: irradiantie, excitatiegeometrie, collectie-efficiëntie, autofluorescentie, de 
hoeveelheid melanine, bloedvolume, bloedoxygenatie en de weefselverstrooiing, werden 
gevarieerd over een bereik zoals dat verwacht kan worden tijdens in vivo beeldvorming. We 
maakten daarbij gebruik van de optische eigenschappen van menselijke huid die een 
porphyrine-achtige fluorofoor bevatte. 
 Het ongecorrigeerde fluorescentiesignaal veranderde meer dan drie ordes van 
grootte. Met de methode van Saarnak et al. veranderde het fluorescentiesignaal niet en was de 
correctie dus compleet, maar deze methode vereist een identieke geometrie voor en na 
toediening van de fluorofoor. De methode van Sinaasappel et al. resulteerde in een 
onzekerheid in het fluorescentiesignaal van maximaal ±20%.  
Deze methodes kunnen dus gebruikt worden voor verbetering van de 
kwantificatienauwkeurigheid van nieuwe actief-gerichte fluoroforen.  
 
Zoals beschreven in Hoofdstuk 6 vormt accurate in vivo kwantificatie van het 
gemeten fluorescentiesignaal een uitdaging. Om dit probleem aan te pakken wordt in 
Hoofdstuk 7 een kwantificatie methode geintroduceerd. De kwantificatieprestaties werden 
geëvalueerd door te modelleren gebruik maakend van optische eigenschappen die 
overeenkwamen met biologisch weefsel, en de fluorescerende marker protoporphyrine IX.  
De kwantificatieprestatie werd experimenteel geëvalueerd in optische fantomen met 
een prototype fluorescentiebeeldvormingssysteem. Dit apparaat kan de methode berekenen 
en weergeven met directe terugkoppeling. De klinische haalbaarheid van het gebruik van 
deze methode en prototype voor beeldvorming-geassisteerde chirurgie werd onderzocht in 
patiënten met prostaatkanker.  
In de discussie wordt besproken waarom deze methode leidt tot een verbetering in 
the kwantifikatieprestatie. Ook worden modificaties gepresenteerd zodat deze methode 
toegepast kan worden met nieuwe actief-doelgerichte markers zoals phthalocyanine 4 en 
dubbel-fluorescerende markers. De toegevoegde waarde hiervan is dat deze een lineaire 
response hebben ten opzichte van de marker concentratie en de invloed van 
autofluorescentie en optische eigenschappen minimaliseren. Dit werd gedemonstreerd door 
te modelleren. 
 
Concluderend hebben we de eerste stappen gezet in de ontwikkeling van basismethodes en 
beeldvormingstechnologie die vereist zijn voor klinische in vivo moleculaire beeldvorming. 
De grote uitdaging waarop toekomstig werk zich zou moeten richten is het experimenteel en 
klinisch valideren van de hier geïntroduceerde methodes en technieken. 
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General Discussion  
 
Over the course of this PhD research several significant advances have been made in 
the field of optical fluorescence imaging for biomedical applications.   
 
Optical imaging of fluorescent markers will likely soon have an impact on clinical 
practice. This primarily because a European group recently completed a multi-centre Phase 
III trial in 270 patients. Here fluorescence-image guidance was investigated for the resection 
of malignant gliomas, using the fluorescent marker PpIX. Their results demonstrated that 
patients allocated to fluorescence guidance had double the 6-month progression free survival 
rates as compred to those allocated to white light (41.0% [32.8-49.2] vs 21.1% [14.0-28.2]; 
difference between groups 19.9% [9.1-30.7], p=0.0003, Z test) (1). These results may be 
strong enough to warrant the first regulatory approval of fluorescence guided resection in 
oncology in the near future. 
 
Further, the interest in optical imaging of fluorescent markers in vivo has 
tremendously increased. What less than 10 years ago was a relatively small research field, is 
now a very rapidly evolving field (2). What spiked this interest are recent advances in 
nanotechnology and increasing knowledge of genes and proteins associated with cancers. 
This combination has led to the development of engineered nanoparticles that comprises a 
fluorescent marker and a targeting moiety. Such active-targeting fluorescent markers hold 
promise to have an increased more stable spectral intensity and improved tumor specificity 
over previous passive-targeting makers (3). At the fluorescent marker end, various strongly 
fluorescent organic dyes have been synthesized (4, 5) as well as nanocrystals that have a high 
spectral intensity and allow tuning of the emission wavelength (6). Further, various ‘smart’ 
fluorescent markers have been developed. Some markers can be switched on in the presence 
of an enzyme (7), while others are self-illuminating and do not require external excitation 
light (8). Onto the same targeting moiety, there is also potential for combining fluorescent 
markers with MR-, PET-, SPECT- and US sensitive (nano)particles for multi-modality 
imaging (9). As for the targeting moiety, an increasing amount of molecular markers 
continue to be reported on almost a daily basis.  Hence, the combinations of fluorescent 
markers and targeting moieties seem to offer endless new opportunities that are currently 
largely unexplored.   
 
Besides yielding information about the presence or absence of disease (as was 
typically the case for passive-targeting fluorescent markers) various active-targeting markers 
also allow real-time in vivo monitoring of disease progression, response to treatment and 
reveal information about the stage of the disease, disease mechanisms and various 
prognostic factors (10). The ability to measure functional disease information in vivo, in real-
time is quite revolutionary. Prior to the availability of these markers it was simply not feasible 
to measure such information in vivo and could only be approximated by ex vivo techniques. 
 
As this field is yet only in its infancy, it is not clear what implications these advances 
will have long-term. It is, however, highly anticipated that an in vivo imaging of receptor-
targeted-fluorescent markers will find wide application in drug discovery, immunology, 
cancer research and clinical practice (3).  
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For this to happen, one challenge is that these advances in active-targeting 
fluorescent markers will need to be matched by appropriate imaging methods and 
technologies designed optimally for specific applications. In this thesis we have made 
significant contributions to this challenge. Specifically, we have investigated existing and 
developed novel methods for in vivo quantification of fluorescent markers in real-time. This 
is of value as fluorescence quantification is critical to yield reliable functional disease 
information. Evaluation of the quantification performance was performed through 
mathematical modeling and via in vivo preclinical models. The feasibility of using these 
methods for diagnostic screening and surgical guidance was demonstrated in patients during 
clinical pilot studies.  
 
Throughout this thesis we have shown that the quantification methods introduced 
here significantly improve the fluorescence image quantification over the current state of the 
art.  Hence, these methods may find acceptance in those applications where in vivo real-time 
fluorescence quantification is critical, as diagnostic screening and image-guided surgery. 
 
Ongoing clinical trials with the methods and technology developed herein will, a) 
validate the utility of fluorescence imaging in tumor detection and guided surgery, b) 
determine the efficacy and possible limitations of current fluorescent markers, and c) 
establish the core imaging hardware/software technology platform and algorithms needed 
for clinical in vivo fluorescent molecular imaging.  
 
Imagine all the possibilities of fluorescence imaging and one comes to realize that there is an exciting and 
brightly fluorescing future ahead of us ! 
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